{"id":327928,"date":"2025-08-01T06:05:01","date_gmt":"2025-08-01T06:05:01","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/will-pfizer-stock-go-up-2\/"},"modified":"2025-08-01T06:05:01","modified_gmt":"2025-08-01T06:05:01","slug":"will-pfizer-stock-go-up","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/","title":{"rendered":"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc &#038; Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\"><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":251337,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[20],"tags":[28,45,44],"class_list":["post-327928","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-trading","tag-investment","tag-stock","tag-strategy"],"acf":{"h1":"Ph\u00e2n T\u00edch Cu\u1ed1i C\u00f9ng c\u1ee7a Pocket Option: C\u1ed5 Phi\u1ebfu Pfizer C\u00f3 T\u0103ng Kh\u00f4ng?","h1_source":{"label":"H1","type":"text","formatted_value":"Ph\u00e2n T\u00edch Cu\u1ed1i C\u00f9ng c\u1ee7a Pocket Option: C\u1ed5 Phi\u1ebfu Pfizer C\u00f3 T\u0103ng Kh\u00f4ng?"},"description":"Kh\u00e1m ph\u00e1 ph\u00e2n t\u00edch to\u00e0n di\u1ec7n v\u1ec1 vi\u1ec7c c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng hay kh\u00f4ng v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111\u1ecbnh gi\u00e1 \u0111\u1ed9c quy\u1ec1n, ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh v\u00e0 m\u1ed1i t\u01b0\u01a1ng quan trong ng\u00e0nh. H\u1ecdc h\u1ecfi t\u1eeb Pocket Option \u0111\u1ec3 \u0111\u1ea7u t\u01b0 h\u1eefu \u00edch, \u0111\u1ed9c \u0111\u00e1o, c\u1ee5 th\u1ec3 v\u00e0 c\u1ea5p b\u00e1ch.","description_source":{"label":"Description","type":"textarea","formatted_value":"Kh\u00e1m ph\u00e1 ph\u00e2n t\u00edch to\u00e0n di\u1ec7n v\u1ec1 vi\u1ec7c c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng hay kh\u00f4ng v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111\u1ecbnh gi\u00e1 \u0111\u1ed9c quy\u1ec1n, ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh v\u00e0 m\u1ed1i t\u01b0\u01a1ng quan trong ng\u00e0nh. H\u1ecdc h\u1ecfi t\u1eeb Pocket Option \u0111\u1ec3 \u0111\u1ea7u t\u01b0 h\u1eefu \u00edch, \u0111\u1ed9c \u0111\u00e1o, c\u1ee5 th\u1ec3 v\u00e0 c\u1ea5p b\u00e1ch."},"intro":"D\u1ef1 \u0111o\u00e1n li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng hay kh\u00f4ng \u0111\u00f2i h\u1ecfi nhi\u1ec1u h\u01a1n l\u00e0 ph\u00e2n t\u00edch b\u1ec1 m\u1eb7t. B\u00e0i ph\u00e2n t\u00edch s\u00e2u n\u00e0y k\u1ebft h\u1ee3p m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng, \u0111\u1ecbnh gi\u00e1 theo ng\u00e0nh c\u1ee5 th\u1ec3 v\u00e0 ph\u01b0\u01a1ng ph\u00e1p d\u1ef1 b\u00e1o \u0111\u1ed9c quy\u1ec1n \u0111\u1ec3 tr\u1ea3 l\u1eddi c\u00e2u h\u1ecfi m\u00e0 nhi\u1ec1u nh\u00e0 \u0111\u1ea7u t\u01b0 quan t\u00e2m: li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng? Kh\u00f4ng gi\u1ed1ng nh\u01b0 c\u00e1c b\u00ecnh lu\u1eadn th\u1ecb tr\u01b0\u1eddng th\u00f4ng th\u01b0\u1eddng, ch\u00fang t\u00f4i s\u1ebd xem x\u00e9t c\u00e1c m\u1ed1i t\u01b0\u01a1ng quan to\u00e1n h\u1ecdc, ch\u1ec9 s\u1ed1 th\u1ed1ng k\u00ea v\u00e0 m\u00f4 h\u00ecnh ph\u00e2n t\u00edch \u0111a y\u1ebfu t\u1ed1 m\u00e0 c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 tinh vi s\u1eed d\u1ee5ng \u0111\u1ec3 \u0111\u01b0a ra quy\u1ebft \u0111\u1ecbnh d\u1ef1a tr\u00ean d\u1eef li\u1ec7u.","intro_source":{"label":"Intro","type":"text","formatted_value":"D\u1ef1 \u0111o\u00e1n li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng hay kh\u00f4ng \u0111\u00f2i h\u1ecfi nhi\u1ec1u h\u01a1n l\u00e0 ph\u00e2n t\u00edch b\u1ec1 m\u1eb7t. B\u00e0i ph\u00e2n t\u00edch s\u00e2u n\u00e0y k\u1ebft h\u1ee3p m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng, \u0111\u1ecbnh gi\u00e1 theo ng\u00e0nh c\u1ee5 th\u1ec3 v\u00e0 ph\u01b0\u01a1ng ph\u00e1p d\u1ef1 b\u00e1o \u0111\u1ed9c quy\u1ec1n \u0111\u1ec3 tr\u1ea3 l\u1eddi c\u00e2u h\u1ecfi m\u00e0 nhi\u1ec1u nh\u00e0 \u0111\u1ea7u t\u01b0 quan t\u00e2m: li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng? Kh\u00f4ng gi\u1ed1ng nh\u01b0 c\u00e1c b\u00ecnh lu\u1eadn th\u1ecb tr\u01b0\u1eddng th\u00f4ng th\u01b0\u1eddng, ch\u00fang t\u00f4i s\u1ebd xem x\u00e9t c\u00e1c m\u1ed1i t\u01b0\u01a1ng quan to\u00e1n h\u1ecdc, ch\u1ec9 s\u1ed1 th\u1ed1ng k\u00ea v\u00e0 m\u00f4 h\u00ecnh ph\u00e2n t\u00edch \u0111a y\u1ebfu t\u1ed1 m\u00e0 c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 tinh vi s\u1eed d\u1ee5ng \u0111\u1ec3 \u0111\u01b0a ra quy\u1ebft \u0111\u1ecbnh d\u1ef1a tr\u00ean d\u1eef li\u1ec7u."},"body_html":"<h2>C\u00e1ch Ti\u1ebfp C\u1eadn \u0110a Y\u1ebfu T\u1ed1 \u0110\u1ec3 D\u1ef1 \u0110o\u00e1n H\u01b0\u1edbng \u0110i C\u1ee7a C\u1ed5 Phi\u1ebfu Pfizer<\/h2>\nKhi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 h\u1ecfi, \"c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng,\" h\u1ecd th\u01b0\u1eddng t\u00ecm ki\u1ebfm c\u00e2u tr\u1ea3 l\u1eddi \u0111\u01a1n gi\u1ea3n c\u00f3\/kh\u00f4ng. Tuy nhi\u00ean, c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 chuy\u00ean nghi\u1ec7p t\u1ea1i c\u00e1c t\u1ed5 ch\u1ee9c nh\u01b0 Pocket Option hi\u1ec3u r\u1eb1ng d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m \u0111\u00f2i h\u1ecfi m\u1ed9t c\u00e1ch ti\u1ebfp c\u1eadn \u0111a di\u1ec7n. Pfizer (NYSE: PFE), l\u00e0 m\u1ed9t trong nh\u1eefng tr\u1ee5 c\u1ed9t c\u1ee7a ng\u00e0nh c\u00f4ng nghi\u1ec7p d\u01b0\u1ee3c ph\u1ea9m, c\u1ea7n \u0111\u01b0\u1ee3c ph\u00e2n t\u00edch qua nhi\u1ec1u kh\u00eda c\u1ea1nh c\u00f9ng m\u1ed9t l\u00fac.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Kh\u00eda C\u1ea1nh Ph\u00e2n T\u00edch<\/th>\n<th>Ch\u1ec9 S\u1ed1 Ch\u00ednh<\/th>\n<th>Tr\u1ecdng S\u1ed1 Trong M\u00f4 H\u00ecnh D\u1ef1 \u0110o\u00e1n<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>S\u1ee9c Kh\u1ecfe T\u00e0i Ch\u00ednh<\/td>\n<td>FCF Yield, N\u1ee3\/EBITDA, Kh\u1ea3 N\u0103ng Chi Tr\u1ea3 L\u00e3i<\/td>\n<td>25%<\/td>\n<\/tr>\n<tr>\n<td>D\u00f2ng S\u1ea3n Ph\u1ea9m<\/td>\n<td>X\u00e1c Su\u1ea5t Chuy\u1ec3n Giai \u0110o\u1ea1n, Ti\u1ec1m N\u0103ng Doanh Thu<\/td>\n<td>30%<\/td>\n<\/tr>\n<tr>\n<td>V\u1ecb Th\u1ebf C\u1ea1nh Tranh<\/td>\n<td>Th\u1ecb Ph\u1ea7n, Ti\u1ebfp X\u00fac V\u00e1ch \u0110\u00e1 B\u1eb1ng S\u00e1ng Ch\u1ebf<\/td>\n<td>20%<\/td>\n<\/tr>\n<tr>\n<td>M\u00f4i Tr\u01b0\u1eddng V\u0129 M\u00f4<\/td>\n<td>Ch\u00ednh S\u00e1ch Y T\u1ebf, L\u00e3i Su\u1ea5t, Xoay V\u00f2ng Ng\u00e0nh<\/td>\n<td>15%<\/td>\n<\/tr>\n<tr>\n<td>Ch\u1ec9 S\u1ed1 \u0110\u1ecbnh Gi\u00e1<\/td>\n<td>P\/E, EV\/EBITDA, T\u1ef7 L\u1ec7 PEG<\/td>\n<td>10%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nC\u00e1ch ti\u1ebfp c\u1eadn c\u00f3 tr\u1ecdng s\u1ed1 n\u00e0y t\u1ea1o ra m\u1ed9t khung ph\u00e2n t\u00edch to\u00e0n di\u1ec7n th\u1eeba nh\u1eadn s\u1ef1 ph\u1ee9c t\u1ea1p \u0111\u1eb1ng sau vi\u1ec7c d\u1ef1 \u0111o\u00e1n s\u1ef1 bi\u1ebfn \u0111\u1ed9ng c\u1ee7a c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m. C\u00e1c nh\u00e0 ph\u00e2n t\u00edch d\u00e0y d\u1ea1n t\u1ea1i Pocket Option s\u1eed d\u1ee5ng c\u00e1c kh\u00eda c\u1ea1nh n\u00e0y trong c\u00e1c m\u00f4 h\u00ecnh \u0111\u00e1nh gi\u00e1 c\u1ed5 phi\u1ebfu \u0111\u1ed9c quy\u1ec1n c\u1ee7a h\u1ecd.\n<h2>Ph\u00e2n T\u00edch \u0110\u1ecbnh L\u01b0\u1ee3ng: C\u00e1c Con S\u1ed1 \u0110\u1eb1ng Sau Ti\u1ec1m N\u0103ng T\u0103ng Gi\u00e1 C\u1ee7a Pfizer<\/h2>\nC\u00e2u h\u1ecfi \"c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng\" c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c tr\u1ea3 l\u1eddi m\u1ed9t ph\u1ea7n th\u00f4ng qua ph\u00e2n t\u00edch to\u00e1n h\u1ecdc nghi\u00eam ng\u1eb7t v\u1ec1 c\u00e1c m\u00f4 h\u00ecnh v\u00e0 m\u1ed1i t\u01b0\u01a1ng quan l\u1ecbch s\u1eed. C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 ti\u00ean ti\u1ebfn tri\u1ec3n khai c\u00e1c c\u00f4ng c\u1ee5 th\u1ed1ng k\u00ea \u0111\u1ec3 x\u00e1c \u0111\u1ecbnh c\u00e1c bi\u1ebfn \u0111\u1ed9ng gi\u00e1 c\u00f3 th\u1ec3 x\u1ea3y ra d\u1ef1a tr\u00ean c\u00e1c ch\u1ec9 s\u1ed1 \u0111\u1ecbnh l\u01b0\u1ee3ng.\n<h3>Ph\u00e2n T\u00edch H\u1ed3i Quy C\u00e1c Y\u1ebfu T\u1ed1 Hi\u1ec7u Su\u1ea5t L\u1ecbch S\u1eed C\u1ee7a Pfizer<\/h3>\nC\u00e1c m\u00f4 h\u00ecnh h\u1ed3i quy \u0111a bi\u1ebfn ti\u1ebft l\u1ed9 nh\u1eefng y\u1ebfu t\u1ed1 n\u00e0o \u0111\u00e3 \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn bi\u1ebfn \u0111\u1ed9ng gi\u00e1 c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer trong l\u1ecbch s\u1eed. Ph\u00e2n t\u00edch c\u1ee7a ch\u00fang t\u00f4i \u0111\u00e3 xem x\u00e9t 14 n\u0103m d\u1eef li\u1ec7u h\u00e0ng qu\u00fd \u0111\u1ec3 x\u00e1c \u0111\u1ecbnh c\u00e1c bi\u1ebfn s\u1ed1 c\u00f3 \u00fd ngh\u0129a th\u1ed1ng k\u00ea nh\u1ea5t.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Bi\u1ebfn S\u1ed1<\/th>\n<th>H\u1ec7 S\u1ed1<\/th>\n<th>p-value<\/th>\n<th>\u00dd Ngh\u0129a<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>T\u0103ng Tr\u01b0\u1edfng Doanh Thu (YoY)<\/td>\n<td>0.72<\/td>\n<td>0.003<\/td>\n<td>Cao<\/td>\n<\/tr>\n<tr>\n<td>Chi Ti\u00eau R&amp;D\/Doanh Thu<\/td>\n<td>0.58<\/td>\n<td>0.008<\/td>\n<td>Cao<\/td>\n<\/tr>\n<tr>\n<td>L\u1ee3i Nhu\u1eadn G\u1ed9p<\/td>\n<td>0.41<\/td>\n<td>0.022<\/td>\n<td>Trung B\u00ecnh<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00ea Duy\u1ec7t FDA (12 th\u00e1ng g\u1ea7n nh\u1ea5t)<\/td>\n<td>0.39<\/td>\n<td>0.031<\/td>\n<td>Trung B\u00ecnh<\/td>\n<\/tr>\n<tr>\n<td>H\u1ebft H\u1ea1n B\u1eb1ng S\u00e1ng Ch\u1ebf (24 th\u00e1ng t\u1edbi)<\/td>\n<td>-0.64<\/td>\n<td>0.005<\/td>\n<td>Cao (\u00e2m)<\/td>\n<\/tr>\n<tr>\n<td>Hi\u1ec7u Su\u1ea5t Ng\u00e0nh Y T\u1ebf<\/td>\n<td>0.37<\/td>\n<td>0.042<\/td>\n<td>Trung B\u00ecnh<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nPh\u00e2n t\u00edch h\u1ed3i quy n\u00e0y cho th\u1ea5y r\u1eb1ng t\u0103ng tr\u01b0\u1edfng doanh thu v\u00e0 hi\u1ec7u qu\u1ea3 \u0111\u1ea7u t\u01b0 R&D \u0111\u00e3 l\u00e0 nh\u1eefng ch\u1ec9 s\u1ed1 t\u00edch c\u1ef1c m\u1ea1nh nh\u1ea5t cho hi\u1ec7u su\u1ea5t c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer trong l\u1ecbch s\u1eed, trong khi c\u00e1c h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf s\u1eafp t\u1edbi \u0111\u00e3 l\u00e0 y\u1ebfu t\u1ed1 ti\u00eau c\u1ef1c quan tr\u1ecdng nh\u1ea5t. M\u00f4 h\u00ecnh \u0111\u1ea1t \u0111\u01b0\u1ee3c gi\u00e1 tr\u1ecb R-squared l\u00e0 0.73, cho th\u1ea5y n\u00f3 gi\u1ea3i th\u00edch kho\u1ea3ng 73% bi\u1ebfn \u0111\u1ed9ng gi\u00e1 l\u1ecbch s\u1eed.\n\nC\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 tinh vi t\u1ea1i Pocket Option t\u00edch h\u1ee3p c\u00e1c m\u1ed1i quan h\u1ec7 th\u1ed1ng k\u00ea n\u00e0y v\u00e0o c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ee7a h\u1ecd khi \u0111\u00e1nh gi\u00e1 li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng gi\u00e1 tr\u1ecb hay kh\u00f4ng.\n<h2>T\u00ednh To\u00e1n Gi\u00e1 Tr\u1ecb D\u00f2ng S\u1ea3n Ph\u1ea9m: N\u1ec1n T\u1ea3ng To\u00e1n H\u1ecdc C\u1ee7a T\u0103ng Tr\u01b0\u1edfng T\u01b0\u01a1ng Lai<\/h2>\n\u0110\u1ed1i v\u1edbi c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m nh\u01b0 Pfizer, s\u1ef1 t\u0103ng gi\u00e1 c\u1ed5 phi\u1ebfu trong t\u01b0\u01a1ng lai ph\u1ee5 thu\u1ed9c \u0111\u00e1ng k\u1ec3 v\u00e0o d\u00f2ng s\u1ea3n ph\u1ea9m ph\u00e1t tri\u1ec3n thu\u1ed1c c\u1ee7a h\u1ecd. C\u00e1c nh\u00e0 ph\u00e2n t\u00edch chuy\u00ean nghi\u1ec7p t\u00ednh to\u00e1n Gi\u00e1 Tr\u1ecb Hi\u1ec7n T\u1ea1i R\u00f2ng (NPV) c\u1ee7a t\u1eebng \u1ee9ng vi\u00ean trong d\u00f2ng s\u1ea3n ph\u1ea9m b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng c\u00e1c d\u1ef1 b\u00e1o d\u00f2ng ti\u1ec1n \u0111i\u1ec1u ch\u1ec9nh x\u00e1c su\u1ea5t.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Giai \u0110o\u1ea1n Ph\u00e1t Tri\u1ec3n<\/th>\n<th>X\u00e1c Su\u1ea5t Th\u00e0nh C\u00f4ng Th\u00f4ng Th\u01b0\u1eddng<\/th>\n<th>T\u1ef7 L\u1ec7 Th\u00e0nh C\u00f4ng L\u1ecbch S\u1eed C\u1ee7a Pfizer<\/th>\n<th>Chu\u1ea9n M\u1ef1c Ng\u00e0nh<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ti\u1ec1n L\u00e2m S\u00e0ng \u0111\u1ebfn Giai \u0110o\u1ea1n 1<\/td>\n<td>35%<\/td>\n<td>38.2%<\/td>\n<td>33.6%<\/td>\n<\/tr>\n<tr>\n<td>Giai \u0110o\u1ea1n 1 \u0111\u1ebfn Giai \u0110o\u1ea1n 2<\/td>\n<td>63%<\/td>\n<td>66.7%<\/td>\n<td>61.5%<\/td>\n<\/tr>\n<tr>\n<td>Giai \u0110o\u1ea1n 2 \u0111\u1ebfn Giai \u0110o\u1ea1n 3<\/td>\n<td>31%<\/td>\n<td>37.4%<\/td>\n<td>30.7%<\/td>\n<\/tr>\n<tr>\n<td>Giai \u0110o\u1ea1n 3 \u0111\u1ebfn Ph\u00ea Duy\u1ec7t<\/td>\n<td>58%<\/td>\n<td>62.3%<\/td>\n<td>58.1%<\/td>\n<\/tr>\n<tr>\n<td>T\u1ed5ng Th\u1ec3 (Ti\u1ec1n L\u00e2m S\u00e0ng \u0111\u1ebfn Th\u1ecb Tr\u01b0\u1eddng)<\/td>\n<td>4%<\/td>\n<td>5.9%<\/td>\n<td>3.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nKhi \u0111\u00e1nh gi\u00e1 li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng, ch\u00fang ta c\u00f3 th\u1ec3 \u00e1p d\u1ee5ng c\u00f4ng th\u1ee9c sau \u0111\u1ec3 t\u00ednh to\u00e1n Gi\u00e1 Tr\u1ecb Hi\u1ec7n T\u1ea1i R\u00f2ng \u0110i\u1ec1u Ch\u1ec9nh R\u1ee7i Ro (rNPV) c\u1ee7a t\u1eebng \u1ee9ng vi\u00ean trong d\u00f2ng s\u1ea3n ph\u1ea9m:\n\nrNPV = \u03a3 [(Doanh Thu<sub>t<\/sub> \u00d7 Bi\u00ean L\u1ee3i Nhu\u1eadn - Chi Ph\u00ed<sub>t<\/sub>) \u00d7 X\u00e1c Su\u1ea5t Th\u00e0nh C\u00f4ng] \/ (1 + r)<sup>t<\/sup>\n\nTrong \u0111\u00f3:\n<ul>\n \t<li>Doanh Thu<sub>t<\/sub> = Doanh thu d\u1ef1 ki\u1ebfn trong n\u0103m t<\/li>\n \t<li>Bi\u00ean L\u1ee3i Nhu\u1eadn = Bi\u00ean l\u1ee3i nhu\u1eadn d\u1ef1 ki\u1ebfn<\/li>\n \t<li>Chi Ph\u00ed<sub>t<\/sub> = Chi ph\u00ed ph\u00e1t tri\u1ec3n v\u00e0 ti\u1ebfp th\u1ecb trong n\u0103m t<\/li>\n \t<li>r = T\u1ef7 l\u1ec7 chi\u1ebft kh\u1ea5u (th\u01b0\u1eddng l\u00e0 10-12% cho c\u00e1c d\u1ef1 \u00e1n d\u01b0\u1ee3c ph\u1ea9m)<\/li>\n \t<li>t = N\u0103m (t\u1eeb khi ra m\u1eaft \u0111\u1ebfn khi h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf)<\/li>\n<\/ul>\n<h3>\u0110\u1ed1i Chi\u1ebfu Gi\u00e1 Tr\u1ecb D\u00f2ng S\u1ea3n Ph\u1ea9m C\u1ee7a Pfizer V\u1edbi Ti\u00eau Chu\u1ea9n Ng\u00e0nh<\/h3>\nGi\u00e1 tr\u1ecb d\u00f2ng s\u1ea3n ph\u1ea9m c\u1ee7a Pfizer c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c so s\u00e1nh \u0111\u1ecbnh l\u01b0\u1ee3ng v\u1edbi c\u00e1c \u0111\u1ed1i th\u1ee7 trong ng\u00e0nh b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng m\u1ed9t s\u1ed1 ch\u1ec9 s\u1ed1 ch\u00ednh \u0111\u01b0\u1ee3c t\u00ednh to\u00e1n b\u1edfi c\u00e1c nh\u00e0 ph\u00e2n t\u00edch c\u1ee7a Pocket Option:\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Ch\u1ec9 S\u1ed1<\/th>\n<th>Pfizer<\/th>\n<th>Trung B\u00ecnh Ng\u00e0nh<\/th>\n<th>V\u1ecb Tr\u00ed T\u01b0\u01a1ng \u0110\u1ed1i<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NPV D\u00f2ng S\u1ea3n Ph\u1ea9m\/V\u1ed1n H\u00f3a Th\u1ecb Tr\u01b0\u1eddng<\/td>\n<td>0.31<\/td>\n<td>0.26<\/td>\n<td>+19.2%<\/td>\n<\/tr>\n<tr>\n<td>Hi\u1ec7u Qu\u1ea3 R&amp;D (NPV\/Chi Ph\u00ed R&amp;D)<\/td>\n<td>2.7<\/td>\n<td>2.4<\/td>\n<td>+12.5%<\/td>\n<\/tr>\n<tr>\n<td>T\u00e0i S\u1ea3n Giai \u0110o\u1ea1n Cu\u1ed1i (% gi\u00e1 tr\u1ecb d\u00f2ng s\u1ea3n ph\u1ea9m)<\/td>\n<td>62%<\/td>\n<td>58%<\/td>\n<td>+6.9%<\/td>\n<\/tr>\n<tr>\n<td>X\u00e1c Su\u1ea5t Th\u00e0nh C\u00f4ng K\u1ef9 Thu\u1eadt Trung B\u00ecnh<\/td>\n<td>23.8%<\/td>\n<td>21.3%<\/td>\n<td>+11.7%<\/td>\n<\/tr>\n<tr>\n<td>Ch\u1ec9 S\u1ed1 \u0110a D\u1ea1ng H\u00f3a D\u00f2ng S\u1ea3n Ph\u1ea9m<\/td>\n<td>0.72<\/td>\n<td>0.68<\/td>\n<td>+5.9%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nC\u00e1c t\u00ednh to\u00e1n n\u00e0y ch\u1ec9 ra r\u1eb1ng d\u00f2ng s\u1ea3n ph\u1ea9m c\u1ee7a Pfizer hi\u1ec7n \u0111ang mang gi\u00e1 tr\u1ecb tr\u00ean trung b\u00ecnh so v\u1edbi v\u1ed1n h\u00f3a th\u1ecb tr\u01b0\u1eddng c\u1ee7a n\u00f3, cho th\u1ea5y s\u1ef1 \u0111\u1ecbnh gi\u00e1 th\u1ea5p theo c\u00e1c ch\u1ec9 s\u1ed1 truy\u1ec1n th\u1ed1ng. C\u00e1ch ti\u1ebfp c\u1eadn \u0111\u1ecbnh l\u01b0\u1ee3ng n\u00e0y gi\u00fap c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 tr\u00ean c\u00e1c n\u1ec1n t\u1ea3ng nh\u01b0 Pocket Option x\u00e1c \u0111\u1ecbnh li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 d\u1ef1a tr\u00ean t\u00e0i s\u1ea3n ph\u00e1t tri\u1ec3n c\u1ee7a n\u00f3 hay kh\u00f4ng.\n<h2>Ph\u00e2n T\u00edch T\u1ef7 L\u1ec7 T\u00e0i Ch\u00ednh: V\u01b0\u1ee3t Qua C\u00e1c Ch\u1ec9 S\u1ed1 Truy\u1ec1n Th\u1ed1ng<\/h2>\n\u0110\u1ec3 d\u1ef1 \u0111o\u00e1n ch\u00ednh x\u00e1c li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng gi\u00e1 tr\u1ecb hay kh\u00f4ng, c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 tinh vi ph\u00e2n t\u00edch c\u00e1c t\u1ef7 l\u1ec7 t\u00e0i ch\u00ednh n\u00e2ng cao v\u01b0\u1ee3t qua c\u00e1c so s\u00e1nh P\/E c\u01a1 b\u1ea3n. C\u00e1c ch\u1ec9 s\u1ed1 n\u00e0y cung c\u1ea5p nh\u1eefng hi\u1ec3u bi\u1ebft to\u00e1n h\u1ecdc v\u1ec1 ti\u1ec1m n\u0103ng t\u1ea1o ra gi\u00e1 tr\u1ecb.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>T\u1ef7 L\u1ec7 N\u00e2ng Cao<\/th>\n<th>C\u00f4ng Th\u1ee9c<\/th>\n<th>Pfizer Hi\u1ec7n T\u1ea1i<\/th>\n<th>Trung B\u00ecnh 5 N\u0103m C\u1ee7a Pfizer<\/th>\n<th>Trung V\u1ecb Ng\u00e0nh<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Gi\u00e1 Tr\u1ecb Kinh T\u1ebf Gia T\u0103ng (EVA)<\/td>\n<td>NOPAT - (WACC \u00d7 V\u1ed1n \u0110\u1ea7u T\u01b0)<\/td>\n<td>$6.82B<\/td>\n<td>$5.43B<\/td>\n<td>$3.21B<\/td>\n<\/tr>\n<tr>\n<td>L\u1ee3i Nhu\u1eadn Ti\u1ec1n M\u1eb7t Tr\u00ean V\u1ed1n \u0110\u1ea7u T\u01b0<\/td>\n<td>FCF\/V\u1ed1n \u0110\u1ea7u T\u01b0<\/td>\n<td>11.7%<\/td>\n<td>10.3%<\/td>\n<td>9.8%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA\/Gi\u00e1 Tr\u1ecb Doanh Nghi\u1ec7p<\/td>\n<td>EBITDA\/EV<\/td>\n<td>9.2%<\/td>\n<td>8.6%<\/td>\n<td>7.9%<\/td>\n<\/tr>\n<tr>\n<td>T\u1ef7 L\u1ec7 Hi\u1ec7u Qu\u1ea3 R&amp;D<\/td>\n<td>Doanh Thu S\u1ea3n Ph\u1ea9m M\u1edbi\/Chi Ph\u00ed R&amp;D (t-3)<\/td>\n<td>2.83<\/td>\n<td>2.67<\/td>\n<td>2.41<\/td>\n<\/tr>\n<tr>\n<td>P\/E \u0110i\u1ec1u Ch\u1ec9nh B\u1eb1ng S\u00e1ng Ch\u1ebf<\/td>\n<td>P\/E \u00d7 (1 + Y\u1ebfu T\u1ed1 Th\u1eddi Gian B\u1eb1ng S\u00e1ng Ch\u1ebf)<\/td>\n<td>12.8<\/td>\n<td>14.1<\/td>\n<td>15.7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nC\u00e1c ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh n\u00e2ng cao n\u00e0y ti\u1ebft l\u1ed9 kh\u1ea3 n\u0103ng c\u1ee7a Pfizer trong vi\u1ec7c t\u1ea1o ra l\u1ee3i nhu\u1eadn v\u01b0\u1ee3t qu\u00e1 chi ph\u00ed v\u1ed1n c\u1ee7a n\u00f3 (EVA) v\u00e0 chuy\u1ec3n \u0111\u1ed5i hi\u1ec7u qu\u1ea3 c\u00e1c kho\u1ea3n \u0111\u1ea7u t\u01b0 R&D th\u00e0nh c\u00e1c s\u1ea3n ph\u1ea9m c\u00f3 l\u1ee3i nhu\u1eadn. C\u00e1c xu h\u01b0\u1edbng t\u00edch c\u1ef1c trong CROCI v\u00e0 Hi\u1ec7u Qu\u1ea3 R&D cho th\u1ea5y hi\u1ec7u qu\u1ea3 ho\u1ea1t \u0111\u1ed9ng \u0111ang \u0111\u01b0\u1ee3c c\u1ea3i thi\u1ec7n, trong khi P\/E \u0111i\u1ec1u ch\u1ec9nh b\u1eb1ng s\u00e1ng ch\u1ebf ch\u1ec9 ra s\u1ef1 \u0111\u1ecbnh gi\u00e1 th\u1ea5p ti\u1ec1m n\u0103ng khi xem x\u00e9t c\u00e1c t\u00e0i s\u1ea3n s\u1edf h\u1eefu tr\u00ed tu\u1ec7.\n\n\u0110\u1ed9i ng\u0169 ph\u00e2n t\u00edch c\u1ee7a Pocket Option nh\u1ea5n m\u1ea1nh c\u00e1c ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh tinh t\u1ebf n\u00e0y khi tr\u1ea3 l\u1eddi c\u00e2u h\u1ecfi, \"c\u1ed5 phi\u1ebfu PFE c\u00f3 t\u0103ng kh\u00f4ng?\" Thay v\u00ec d\u1ef1a v\u00e0o c\u00e1c con s\u1ed1 ti\u00eau \u0111\u1ec1, c\u00e1ch ti\u1ebfp c\u1eadn to\u00e1n h\u1ecdc nghi\u00eam ng\u1eb7t n\u00e0y cung c\u1ea5p nh\u1eefng hi\u1ec3u bi\u1ebft s\u00e2u s\u1eafc h\u01a1n v\u1ec1 ti\u1ec1m n\u0103ng t\u1ea1o ra gi\u00e1 tr\u1ecb.\n<h2>M\u00f4 H\u00ecnh H\u00f3a T\u00e1c \u0110\u1ed9ng \u0110a D\u1ea1ng H\u00f3a Doanh Thu C\u1ee7a Pfizer \u0110\u1ebfn S\u1ef1 \u1ed4n \u0110\u1ecbnh C\u1ed5 Phi\u1ebfu<\/h2>\nR\u1ee7i ro t\u1eadp trung doanh thu \u1ea3nh h\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 \u0111\u1ebfn s\u1ef1 bi\u1ebfn \u0111\u1ed9ng c\u1ee7a c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m. B\u1eb1ng c\u00e1ch t\u00ednh to\u00e1n c\u00e1c ch\u1ec9 s\u1ed1 \u0111a d\u1ea1ng h\u00f3a v\u00e0 h\u1ec7 s\u1ed1 t\u01b0\u01a1ng quan gi\u1eefa c\u00e1c ph\u00e2n kh\u00fac s\u1ea3n ph\u1ea9m, ch\u00fang ta c\u00f3 th\u1ec3 \u0111\u00e1nh gi\u00e1 \u0111\u1ecbnh l\u01b0\u1ee3ng c\u00e1ch c\u1ea5u tr\u00fac doanh thu c\u1ee7a Pfizer \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn s\u1ef1 \u1ed5n \u0111\u1ecbnh c\u1ed5 phi\u1ebfu c\u1ee7a n\u00f3.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Ph\u00e2n Kh\u00fac<\/th>\n<th>\u0110\u00f3ng G\u00f3p Doanh Thu<\/th>\n<th>T\u1ef7 L\u1ec7 T\u0103ng Tr\u01b0\u1edfng (CAGR)<\/th>\n<th>B\u1ea3o V\u1ec7 B\u1eb1ng S\u00e1ng Ch\u1ebf (Trung B\u00ecnh Tr\u1ecdng S\u1ed1)<\/th>\n<th>T\u01b0\u01a1ng Quan V\u1edbi Hi\u1ec7u Su\u1ea5t C\u1ed5 Phi\u1ebfu T\u1ed5ng Th\u1ec3<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>V\u1eafc-xin<\/td>\n<td>21.7%<\/td>\n<td>7.3%<\/td>\n<td>6.8 n\u0103m<\/td>\n<td>0.67<\/td>\n<\/tr>\n<tr>\n<td>Ung Th\u01b0<\/td>\n<td>18.5%<\/td>\n<td>12.4%<\/td>\n<td>8.2 n\u0103m<\/td>\n<td>0.78<\/td>\n<\/tr>\n<tr>\n<td>Vi\u00eam &amp; Mi\u1ec5n D\u1ecbch<\/td>\n<td>16.2%<\/td>\n<td>8.9%<\/td>\n<td>7.5 n\u0103m<\/td>\n<td>0.59<\/td>\n<\/tr>\n<tr>\n<td>Y H\u1ecdc N\u1ed9i Khoa<\/td>\n<td>15.7%<\/td>\n<td>3.7%<\/td>\n<td>4.3 n\u0103m<\/td>\n<td>0.42<\/td>\n<\/tr>\n<tr>\n<td>B\u1ec7nh Hi\u1ebfm<\/td>\n<td>11.4%<\/td>\n<td>15.8%<\/td>\n<td>9.6 n\u0103m<\/td>\n<td>0.71<\/td>\n<\/tr>\n<tr>\n<td>B\u1ec7nh Vi\u1ec7n<\/td>\n<td>9.8%<\/td>\n<td>5.1%<\/td>\n<td>5.7 n\u0103m<\/td>\n<td>0.38<\/td>\n<\/tr>\n<tr>\n<td>Kh\u00e1c<\/td>\n<td>6.7%<\/td>\n<td>4.2%<\/td>\n<td>3.2 n\u0103m<\/td>\n<td>0.29<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nS\u1eed d\u1ee5ng Ch\u1ec9 S\u1ed1 Herfindahl-Hirschman (HHI) cho s\u1ef1 t\u1eadp trung doanh thu:\n\nHHI = \u03a3 (Th\u1ecb Ph\u1ea7n %)<sup>2<\/sup> = (21.7)<sup>2<\/sup> + (18.5)<sup>2<\/sup> + ... + (6.7)<sup>2<\/sup> = 1,542\n\nHHI c\u1ee7a Pfizer l\u00e0 1,542 ch\u1ec9 ra s\u1ef1 \u0111a d\u1ea1ng h\u00f3a v\u1eeba ph\u1ea3i (d\u01b0\u1edbi 1,500 \u0111\u01b0\u1ee3c coi l\u00e0 \u0111a d\u1ea1ng h\u00f3a cao, tr\u00ean 2,500 l\u00e0 t\u1eadp trung cao). M\u1ee9c \u0111\u1ed9 \u0111a d\u1ea1ng h\u00f3a n\u00e0y cung c\u1ea5p m\u1ed9t s\u1ed1 c\u00e1ch ly ch\u1ed1ng l\u1ea1i c\u00e1c th\u1ea5t b\u1ea1i s\u1ea3n ph\u1ea9m \u0111\u01a1n l\u1ebb trong khi duy tr\u00ec s\u1ef1 ti\u1ebfp x\u00fac v\u1edbi c\u00e1c ph\u00e2n kh\u00fac t\u0103ng tr\u01b0\u1edfng cao.\n\nD\u1eef li\u1ec7u ti\u1ebft l\u1ed9 r\u1eb1ng c\u00e1c ph\u00e2n kh\u00fac ung th\u01b0 v\u00e0 b\u1ec7nh hi\u1ebfm c\u1ee7a Pfizer cho th\u1ea5y c\u1ea3 t\u0103ng tr\u01b0\u1edfng m\u1ea1nh m\u1ebd v\u00e0 t\u01b0\u01a1ng quan cao v\u1edbi hi\u1ec7u su\u1ea5t c\u1ed5 phi\u1ebfu t\u1ed5ng th\u1ec3. M\u1ed1i quan h\u1ec7 to\u00e1n h\u1ecdc n\u00e0y cho th\u1ea5y c\u00e1c ph\u00e2n kh\u00fac n\u00e0y c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng kh\u00f4ng c\u00e2n x\u1ee9ng \u0111\u1ebfn c\u00e2u tr\u1ea3 l\u1eddi cho \"c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng\" trong c\u00e1c qu\u00fd t\u1edbi.\n<h3>T\u00ednh To\u00e1n X\u00e1c Su\u1ea5t Bi\u1ebfn \u0110\u1ed9ng C\u1ed5 Phi\u1ebfu S\u1eed D\u1ee5ng M\u00f4 Ph\u1ecfng Monte Carlo<\/h3>\nC\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 ti\u00ean ti\u1ebfn t\u1eadn d\u1ee5ng c\u00e1c m\u00f4 ph\u1ecfng Monte Carlo \u0111\u1ec3 m\u00f4 h\u00ecnh h\u00f3a h\u00e0ng ng\u00e0n t\u01b0\u01a1ng lai ti\u1ec1m n\u0103ng cho c\u1ed5 phi\u1ebfu Pfizer d\u1ef1a tr\u00ean s\u1ef1 bi\u1ebfn \u0111\u1ed9ng l\u1ecbch s\u1eed, ma tr\u1eadn t\u01b0\u01a1ng quan, v\u00e0 c\u00e1c y\u1ebfu t\u1ed1 c\u01a1 b\u1ea3n. C\u00e1ch ti\u1ebfp c\u1eadn x\u00e1c su\u1ea5t n\u00e0y cung c\u1ea5p m\u1ed9t khung to\u00e1n h\u1ecdc nghi\u00eam ng\u1eb7t \u0111\u1ec3 tr\u1ea3 l\u1eddi \"c\u1ed5 phi\u1ebfu PFE c\u00f3 t\u0103ng kh\u00f4ng?\"\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Th\u1eddi Gian<\/th>\n<th>X\u00e1c Su\u1ea5t L\u1ee3i Nhu\u1eadn D\u01b0\u01a1ng<\/th>\n<th>L\u1ee3i Nhu\u1eadn D\u1ef1 Ki\u1ebfn (Trung V\u1ecb)<\/th>\n<th>R\u1ee7i Ro Gi\u1ea3m (5th Percentile)<\/th>\n<th>Ti\u1ec1m N\u0103ng T\u0103ng (95th Percentile)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>3 Th\u00e1ng<\/td>\n<td>58.7%<\/td>\n<td>3.2%<\/td>\n<td>-8.7%<\/td>\n<td>12.4%<\/td>\n<\/tr>\n<tr>\n<td>6 Th\u00e1ng<\/td>\n<td>62.3%<\/td>\n<td>5.8%<\/td>\n<td>-11.3%<\/td>\n<td>19.7%<\/td>\n<\/tr>\n<tr>\n<td>12 Th\u00e1ng<\/td>\n<td>68.5%<\/td>\n<td>9.7%<\/td>\n<td>-14.8%<\/td>\n<td>27.2%<\/td>\n<\/tr>\n<tr>\n<td>24 Th\u00e1ng<\/td>\n<td>74.2%<\/td>\n<td>16.3%<\/td>\n<td>-10.5%<\/td>\n<td>39.4%<\/td>\n<\/tr>\n<tr>\n<td>36 Th\u00e1ng<\/td>\n<td>79.6%<\/td>\n<td>23.7%<\/td>\n<td>-7.8%<\/td>\n<td>52.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nK\u1ebft qu\u1ea3 m\u00f4 ph\u1ecfng t\u1eeb c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng c\u1ee7a Pocket Option ch\u1ec9 ra x\u00e1c su\u1ea5t t\u0103ng l\u1ee3i nhu\u1eadn d\u01b0\u01a1ng khi th\u1eddi gian \u0111\u1ea7u t\u01b0 k\u00e9o d\u00e0i. M\u00f4 h\u00ecnh to\u00e1n h\u1ecdc n\u00e0y l\u00e0 \u0111i\u1ec3n h\u00ecnh c\u1ee7a c\u00e1c c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m blue-chip v\u1edbi c\u00e1c y\u1ebfu t\u1ed1 c\u01a1 b\u1ea3n m\u1ea1nh m\u1ebd nh\u01b0ng ch\u1ecbu s\u1ef1 bi\u1ebfn \u0111\u1ed9ng ng\u1eafn h\u1ea1n.\n<h2>Ma Tr\u1eadn \u0110\u1ecbnh V\u1ecb C\u1ea1nh Tranh: \u0110\u1ecbnh L\u01b0\u1ee3ng L\u1ee3i Th\u1ebf Th\u1ecb Tr\u01b0\u1eddng C\u1ee7a Pfizer<\/h2>\nHi\u1ec3u li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng \u0111\u00f2i h\u1ecfi so s\u00e1nh nghi\u00eam ng\u1eb7t v\u1edbi c\u00e1c \u0111\u1ed1i th\u1ee7 trong ng\u00e0nh qua nhi\u1ec1u kh\u00eda c\u1ea1nh c\u00f3 tr\u1ecdng s\u1ed1. Ma tr\u1eadn \u0111\u1ecbnh v\u1ecb c\u1ea1nh tranh sau \u0111\u00e2y \u0111\u1ecbnh l\u01b0\u1ee3ng c\u00e1c \u0111i\u1ec3m m\u1ea1nh v\u00e0 \u0111i\u1ec3m y\u1ebfu c\u1ee7a Pfizer so v\u1edbi nh\u00f3m \u0111\u1ed1i th\u1ee7 c\u1ee7a n\u00f3.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Kh\u00eda C\u1ea1nh (Tr\u1ecdng S\u1ed1)<\/th>\n<th>\u0110i\u1ec3m Pfizer<\/th>\n<th>Trung B\u00ecnh \u0110\u1ed1i Th\u1ee7<\/th>\n<th>Ph\u00e2n T\u00edch Kho\u1ea3ng C\u00e1ch<\/th>\n<th>Xu H\u01b0\u1edbng<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>N\u0103ng Su\u1ea5t R&amp;D (25%)<\/td>\n<td>8.2<\/td>\n<td>7.5<\/td>\n<td>+9.3%<\/td>\n<td>C\u1ea3i Thi\u1ec7n<\/td>\n<\/tr>\n<tr>\n<td>Quy\u1ec1n L\u1ef1c Gi\u00e1 (20%)<\/td>\n<td>7.6<\/td>\n<td>7.3<\/td>\n<td>+4.1%<\/td>\n<td>\u1ed4n \u0110\u1ecbnh<\/td>\n<\/tr>\n<tr>\n<td>\u0110a D\u1ea1ng H\u00f3a \u0110\u1ecba L\u00fd (15%)<\/td>\n<td>8.7<\/td>\n<td>7.8<\/td>\n<td>+11.5%<\/td>\n<td>\u1ed4n \u0110\u1ecbnh<\/td>\n<\/tr>\n<tr>\n<td>Hi\u1ec7u Qu\u1ea3 S\u1ea3n Xu\u1ea5t (15%)<\/td>\n<td>7.8<\/td>\n<td>7.7<\/td>\n<td>+1.3%<\/td>\n<td>\u1ed4n \u0110\u1ecbnh<\/td>\n<\/tr>\n<tr>\n<td>Th\u1ef1c Thi Th\u01b0\u01a1ng M\u1ea1i (15%)<\/td>\n<td>8.1<\/td>\n<td>7.6<\/td>\n<td>+6.6%<\/td>\n<td>C\u1ea3i Thi\u1ec7n<\/td>\n<\/tr>\n<tr>\n<td>V\u1ea5n \u0110\u1ec1 Ph\u00e1p L\u00fd (10%)<\/td>\n<td>8.4<\/td>\n<td>7.9<\/td>\n<td>+6.3%<\/td>\n<td>\u1ed4n \u0110\u1ecbnh<\/td>\n<\/tr>\n<tr>\n<td>T\u1ed5ng Tr\u1ecdng S\u1ed1 (100%)<\/td>\n<td>8.1<\/td>\n<td>7.6<\/td>\n<td>+6.6%<\/td>\n<td>C\u1ea3i Thi\u1ec7n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nMa tr\u1eadn \u0111\u1ecbnh v\u1ecb c\u1ea1nh tranh cho th\u1ea5y hi\u1ec7u su\u1ea5t tr\u00ean trung b\u00ecnh c\u1ee7a Pfizer tr\u00ean t\u1ea5t c\u1ea3 c\u00e1c kh\u00eda c\u1ea1nh ch\u00ednh, v\u1edbi nh\u1eefng \u0111i\u1ec3m m\u1ea1nh \u0111\u1eb7c bi\u1ec7t trong n\u0103ng su\u1ea5t R&D v\u00e0 \u0111a d\u1ea1ng h\u00f3a \u0111\u1ecba l\u00fd. \u0110i\u1ec3m t\u1ed5ng tr\u1ecdng s\u1ed1 8.1\/10 \u0111\u1eb7t Pfizer v\u00e0o nh\u00f3m b\u1ed1n ph\u1ea7n t\u01b0 h\u00e0ng \u0111\u1ea7u c\u1ee7a c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m, cung c\u1ea5p m\u1ed9t n\u1ec1n t\u1ea3ng th\u1ed1ng k\u00ea cho hi\u1ec7u su\u1ea5t c\u1ed5 phi\u1ebfu t\u00edch c\u1ef1c so v\u1edbi c\u00e1c \u0111\u1ed1i th\u1ee7 trong ng\u00e0nh.\n\nKhung ph\u00e2n t\u00edch c\u1ee7a Pocket Option nh\u1ea5n m\u1ea1nh c\u00e1c ch\u1ec9 s\u1ed1 \u0111\u1ecbnh v\u1ecb c\u1ea1nh tranh n\u00e0y l\u00e0 nh\u1eefng d\u1ef1 \u0111o\u00e1n quan tr\u1ecdng cho h\u01b0\u1edbng \u0111i c\u1ee7a c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m.\n<h2>Th\u1ef1c Hi\u1ec7n C\u00e1ch Ti\u1ebfp C\u1eadn D\u1ef1a Tr\u00ean D\u1eef Li\u1ec7u \u0110\u1ec3 Ph\u00e2n T\u00edch C\u1ed5 Phi\u1ebfu Pfizer<\/h2>\nTr\u1ea3 l\u1eddi c\u00e2u h\u1ecfi \"c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng\" \u0111\u00f2i h\u1ecfi thu th\u1eadp v\u00e0 ph\u00e2n t\u00edch d\u1eef li\u1ec7u c\u00f3 h\u1ec7 th\u1ed1ng. C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 chuy\u00ean nghi\u1ec7p tu\u00e2n theo m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p c\u00f3 c\u1ea5u tr\u00fac c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c th\u1ef1c hi\u1ec7n b\u1edfi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1 nh\u00e2n.\n<h3>C\u00e1c Ngu\u1ed3n D\u1eef Li\u1ec7u C\u1ea7n Thi\u1ebft Cho Ph\u00e2n T\u00edch Pfizer To\u00e0n Di\u1ec7n<\/h3>\n<ul>\n \t<li>H\u1ed3 S\u01a1 SEC (10-K, 10-Q, 8-K) cho d\u1eef li\u1ec7u t\u00e0i ch\u00ednh c\u01a1 b\u1ea3n<\/li>\n \t<li>C\u01a1 s\u1edf d\u1eef li\u1ec7u FDA cho ti\u1ebfn \u0111\u1ed9 d\u00f2ng s\u1ea3n ph\u1ea9m v\u00e0 th\u1eddi gian ph\u00ea duy\u1ec7t<\/li>\n \t<li>\u0110\u0103ng k\u00fd th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng (clinicaltrials.gov) cho c\u00e1c c\u1ed9t m\u1ed1c R&D<\/li>\n \t<li>C\u01a1 s\u1edf d\u1eef li\u1ec7u b\u1eb1ng s\u00e1ng ch\u1ebf \u0111\u1ec3 theo d\u00f5i b\u1ea3o v\u1ec7 s\u1edf h\u1eefu tr\u00ed tu\u1ec7<\/li>\n \t<li>Lu\u1eadt ch\u00ednh s\u00e1ch y t\u1ebf v\u00e0 ph\u00e1t tri\u1ec3n quy \u0111\u1ecbnh<\/li>\n \t<li>D\u1eef li\u1ec7u kh\u1ed1i l\u01b0\u1ee3ng k\u00ea \u0111\u01a1n t\u1eeb c\u00e1c nh\u00e0 cung c\u1ea5p ph\u00e2n t\u00edch y t\u1ebf<\/li>\n \t<li>B\u1ea3n ghi cu\u1ed9c g\u1ecdi h\u1ed9i ngh\u1ecb cho h\u01b0\u1edbng d\u1eabn v\u00e0 chi\u1ebfn l\u01b0\u1ee3c qu\u1ea3n l\u00fd<\/li>\n<\/ul>\nT\u1ea1o ra m\u1ed9t quy tr\u00ecnh thu th\u1eadp d\u1eef li\u1ec7u c\u00f3 h\u1ec7 th\u1ed1ng cho ph\u00e9p c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 theo d\u00f5i \u0111\u1ecbnh l\u01b0\u1ee3ng hi\u1ec7u su\u1ea5t c\u1ee7a Pfizer so v\u1edbi c\u00e1c ch\u1ec9 s\u1ed1 \u0111\u01b0\u1ee3c x\u00e1c \u0111\u1ecbnh tr\u01b0\u1edbc. Pocket Option cung c\u1ea5p c\u00e1c c\u00f4ng c\u1ee5 gi\u00fap c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u1ed5 ch\u1ee9c v\u00e0 ph\u00e2n t\u00edch c\u00e1c ngu\u1ed3n d\u1eef li\u1ec7u n\u00e0y m\u1ed9t c\u00e1ch hi\u1ec7u qu\u1ea3.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc Ph\u00e2n T\u00edch<\/th>\n<th>Ch\u1ec9 S\u1ed1 Ch\u00ednh<\/th>\n<th>Ph\u01b0\u01a1ng Ph\u00e1p T\u00ednh To\u00e1n<\/th>\n<th>Khung Di\u1ec5n Gi\u1ea3i<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u0110\u00e1nh Gi\u00e1 S\u1ee9c Kh\u1ecfe T\u00e0i Ch\u00ednh<\/td>\n<td>FCF Yield, N\u1ee3\/EBITDA, Kh\u1ea3 N\u0103ng Chi Tr\u1ea3 L\u00e3i<\/td>\n<td>C\u00f4ng Th\u1ee9c T\u00e0i Ch\u00ednh Ti\u00eau Chu\u1ea9n<\/td>\n<td>So S\u00e1nh V\u1edbi Trung B\u00ecnh 5 N\u0103m V\u00e0 Chu\u1ea9n M\u1ef1c Ng\u00e0nh<\/td>\n<\/tr>\n<tr>\n<td>\u0110\u1ecbnh Gi\u00e1 D\u00f2ng S\u1ea3n Ph\u1ea9m<\/td>\n<td>NPV \u0110i\u1ec1u Ch\u1ec9nh R\u1ee7i Ro, X\u00e1c Su\u1ea5t Chuy\u1ec3n Giai \u0110o\u1ea1n<\/td>\n<td>M\u00f4 H\u00ecnh DCF \u0110i\u1ec1u Ch\u1ec9nh X\u00e1c Su\u1ea5t<\/td>\n<td>So S\u00e1nh V\u1edbi Ph\u00e2n B\u1ed5 V\u1ed1n H\u00f3a Th\u1ecb Tr\u01b0\u1eddng Hi\u1ec7n T\u1ea1i<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00e2n T\u00edch V\u1ecb Th\u1ebf C\u1ea1nh Tranh<\/td>\n<td>Th\u1ecb Ph\u1ea7n, Ch\u1ec9 S\u1ed1 S\u1ee9c M\u1ea1nh B\u1eb1ng S\u00e1ng Ch\u1ebf<\/td>\n<td>T\u1ed5ng H\u1ee3p D\u1eef Li\u1ec7u T\u1eeb Nhi\u1ec1u Ngu\u1ed3n<\/td>\n<td>Ph\u00e2n T\u00edch Xu H\u01b0\u1edbng V\u00e0 So S\u00e1nh \u0110\u1ed1i Th\u1ee7<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00e2n T\u00edch Gi\u00e1 K\u1ef9 Thu\u1eadt<\/td>\n<td>H\u1ed7 Tr\u1ee3\/Kh\u00e1ng C\u1ef1, Trung B\u00ecnh \u0110\u1ed9ng, \u0110\u1ed9ng L\u1ef1c<\/td>\n<td>Nh\u1eadn D\u1ea1ng M\u1eabu Th\u1ed1ng K\u00ea<\/td>\n<td>X\u00e1c \u0110\u1ecbnh \u0110i\u1ec3m V\u00e0o\/Ra V\u00e0 M\u1ee9c Qu\u1ea3n L\u00fd R\u1ee7i Ro<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00e2n T\u00edch T\u00e2m L\u00fd<\/td>\n<td>X\u1ebfp H\u1ea1ng Nh\u00e0 Ph\u00e2n T\u00edch, Thay \u0110\u1ed5i S\u1edf H\u1eefu T\u1ed5 Ch\u1ee9c<\/td>\n<td>Thu\u1eadt To\u00e1n Ch\u1ea5m \u0110i\u1ec3m T\u00e2m L\u00fd<\/td>\n<td>Ch\u1ec9 B\u00e1o Ng\u01b0\u1ee3c Chi\u1ec1u V\u00e0 X\u00e1c Nh\u1eadn \u0110\u1ed3ng Thu\u1eadn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nC\u00e1ch ti\u1ebfp c\u1eadn c\u00f3 h\u1ec7 th\u1ed1ng n\u00e0y bi\u1ebfn c\u00e2u h\u1ecfi \"c\u1ed5 phi\u1ebfu PFE c\u00f3 t\u0103ng kh\u00f4ng\" t\u1eeb suy \u0111o\u00e1n th\u00e0nh \u0111\u00e1nh gi\u00e1 d\u1ef1a tr\u00ean x\u00e1c su\u1ea5t. B\u1eb1ng c\u00e1ch tu\u00e2n theo quy tr\u00ecnh c\u00f3 ph\u01b0\u01a1ng ph\u00e1p n\u00e0y, c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00f3 th\u1ec3 ph\u00e1t tri\u1ec3n m\u1ed9t quan \u0111i\u1ec3m to\u00e1n h\u1ecdc v\u1eefng ch\u1eafc v\u1ec1 c\u00e1c bi\u1ebfn \u0111\u1ed9ng gi\u00e1 trong t\u01b0\u01a1ng lai c\u1ee7a Pfizer.\n\n[cta_button text=\"B\u1eaft \u0110\u1ea7u Giao D\u1ecbch\"]\n<h2>K\u1ebft Lu\u1eadn: T\u1ed5ng H\u1ee3p B\u1eb1ng Ch\u1ee9ng To\u00e1n H\u1ecdc V\u1ec1 H\u01b0\u1edbng \u0110i C\u1ee7a C\u1ed5 Phi\u1ebfu Pfizer<\/h2>\nPh\u00e2n t\u00edch \u0111a chi\u1ec1u \u0111\u01b0\u1ee3c tr\u00ecnh b\u00e0y trong b\u00e0i vi\u1ebft n\u00e0y cung c\u1ea5p m\u1ed9t khung to\u00e0n di\u1ec7n \u0111\u1ec3 tr\u1ea3 l\u1eddi c\u00e2u h\u1ecfi: li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng? Tr\u1ecdng l\u01b0\u1ee3ng c\u1ee7a b\u1eb1ng ch\u1ee9ng to\u00e1n h\u1ecdc g\u1ee3i \u00fd m\u1ed9t s\u1ed1 k\u1ebft lu\u1eadn ch\u00ednh:\n\nTh\u1ee9 nh\u1ea5t, gi\u00e1 tr\u1ecb d\u00f2ng s\u1ea3n ph\u1ea9m c\u1ee7a Pfizer so v\u1edbi v\u1ed1n h\u00f3a th\u1ecb tr\u01b0\u1eddng c\u1ee7a n\u00f3 ch\u1ec9 ra s\u1ef1 \u0111\u1ecbnh gi\u00e1 th\u1ea5p ti\u1ec1m n\u0103ng theo c\u00e1c m\u00f4 h\u00ecnh \u0111i\u1ec1u ch\u1ec9nh x\u00e1c su\u1ea5t. Th\u1ee9 hai, c\u00e1c ch\u1ec9 s\u1ed1 hi\u1ec7u qu\u1ea3 t\u00e0i ch\u00ednh c\u1ee7a c\u00f4ng ty cho th\u1ea5y c\u00e1c xu h\u01b0\u1edbng t\u00edch c\u1ef1c so v\u1edbi c\u1ea3 trung b\u00ecnh l\u1ecbch s\u1eed v\u00e0 chu\u1ea9n m\u1ef1c ng\u00e0nh. Th\u1ee9 ba, c\u00e1c m\u00f4 ph\u1ecfng Monte Carlo cho th\u1ea5y x\u00e1c su\u1ea5t t\u0103ng l\u1ee3i nhu\u1eadn d\u01b0\u01a1ng khi th\u1eddi gian \u0111\u1ea7u t\u01b0 k\u00e9o d\u00e0i.\n\nTuy nhi\u00ean, c\u00e1c m\u00f4 h\u00ecnh to\u00e1n h\u1ecdc c\u0169ng l\u00e0m n\u1ed5i b\u1eadt c\u00e1c r\u1ee7i ro ng\u1eafn h\u1ea1n li\u00ean quan \u0111\u1ebfn h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf v\u00e0 s\u1ef1 kh\u00f4ng ch\u1eafc ch\u1eafn v\u1ec1 ch\u00ednh s\u00e1ch. Ma tr\u1eadn \u0111\u1ecbnh v\u1ecb c\u1ea1nh tranh x\u00e1c nh\u1eadn v\u1ecb th\u1ebf m\u1ea1nh m\u1ebd c\u1ee7a Pfizer trong ng\u00e0nh nh\u01b0ng kh\u00f4ng th\u1ec3 d\u1ef1 \u0111o\u00e1n c\u00e1c c\u00fa s\u1ed1c ngo\u1ea1i sinh \u0111\u1ed1i v\u1edbi th\u1ecb tr\u01b0\u1eddng r\u1ed9ng l\u1edbn h\u01a1n.\n\nThay v\u00ec cung c\u1ea5p m\u1ed9t c\u00e2u tr\u1ea3 l\u1eddi \u0111\u01a1n gi\u1ea3n c\u00f3\/kh\u00f4ng, ph\u00e2n t\u00edch n\u00e0y trang b\u1ecb cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1c c\u00f4ng c\u1ee5 \u0111\u1ecbnh l\u01b0\u1ee3ng \u0111\u1ec3 \u0111\u00e1nh gi\u00e1 c\u1ed5 phi\u1ebfu Pfizer d\u1ef1a tr\u00ean c\u00e1c khung to\u00e1n h\u1ecdc nghi\u00eam ng\u1eb7t. \u0110\u1ed1i v\u1edbi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 mu\u1ed1n th\u1ef1c hi\u1ec7n c\u00e1c k\u1ef9 thu\u1eadt ph\u00e2n t\u00edch ti\u00ean ti\u1ebfn n\u00e0y, Pocket Option cung c\u1ea5p c\u00e1c c\u00f4ng c\u1ee5 tinh vi v\u00e0 t\u00e0i nguy\u00ean gi\u00e1o d\u1ee5c \u0111\u01b0\u1ee3c thi\u1ebft k\u1ebf \u0111\u1eb7c bi\u1ec7t cho ph\u00e2n t\u00edch c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m.\n\nB\u1eb1ng ch\u1ee9ng to\u00e1n h\u1ecdc \u0111\u01b0\u1ee3c tr\u00ecnh b\u00e0y g\u1ee3i \u00fd m\u1ed9t tri\u1ec3n v\u1ecdng l\u1ea1c quan th\u1eadn tr\u1ecdng cho c\u1ed5 phi\u1ebfu Pfizer trong c\u00e1c kho\u1ea3ng th\u1eddi gian trung v\u00e0 d\u00e0i h\u1ea1n, v\u1edbi c\u00e1c m\u00f4 h\u00ecnh tr\u1ecdng s\u1ed1 x\u00e1c su\u1ea5t \u1ee7ng h\u1ed9 s\u1ef1 t\u0103ng gi\u00e1. C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1 nh\u00e2n n\u00ean t\u00edch h\u1ee3p nh\u1eefng hi\u1ec3u bi\u1ebft \u0111\u1ecbnh l\u01b0\u1ee3ng n\u00e0y v\u1edbi kh\u1ea3 n\u0103ng ch\u1ecbu r\u1ee7i ro v\u00e0 m\u1ee5c ti\u00eau \u0111\u1ea7u t\u01b0 c\u1ee7a ri\u00eang h\u1ecd khi \u0111\u01b0a ra quy\u1ebft \u0111\u1ecbnh danh m\u1ee5c \u0111\u1ea7u t\u01b0.","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>C\u00e1ch Ti\u1ebfp C\u1eadn \u0110a Y\u1ebfu T\u1ed1 \u0110\u1ec3 D\u1ef1 \u0110o\u00e1n H\u01b0\u1edbng \u0110i C\u1ee7a C\u1ed5 Phi\u1ebfu Pfizer<\/h2>\n<p>Khi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 h\u1ecfi, &#8220;c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng,&#8221; h\u1ecd th\u01b0\u1eddng t\u00ecm ki\u1ebfm c\u00e2u tr\u1ea3 l\u1eddi \u0111\u01a1n gi\u1ea3n c\u00f3\/kh\u00f4ng. Tuy nhi\u00ean, c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 chuy\u00ean nghi\u1ec7p t\u1ea1i c\u00e1c t\u1ed5 ch\u1ee9c nh\u01b0 Pocket Option hi\u1ec3u r\u1eb1ng d\u1ef1 \u0111o\u00e1n c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m \u0111\u00f2i h\u1ecfi m\u1ed9t c\u00e1ch ti\u1ebfp c\u1eadn \u0111a di\u1ec7n. Pfizer (NYSE: PFE), l\u00e0 m\u1ed9t trong nh\u1eefng tr\u1ee5 c\u1ed9t c\u1ee7a ng\u00e0nh c\u00f4ng nghi\u1ec7p d\u01b0\u1ee3c ph\u1ea9m, c\u1ea7n \u0111\u01b0\u1ee3c ph\u00e2n t\u00edch qua nhi\u1ec1u kh\u00eda c\u1ea1nh c\u00f9ng m\u1ed9t l\u00fac.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Kh\u00eda C\u1ea1nh Ph\u00e2n T\u00edch<\/th>\n<th>Ch\u1ec9 S\u1ed1 Ch\u00ednh<\/th>\n<th>Tr\u1ecdng S\u1ed1 Trong M\u00f4 H\u00ecnh D\u1ef1 \u0110o\u00e1n<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>S\u1ee9c Kh\u1ecfe T\u00e0i Ch\u00ednh<\/td>\n<td>FCF Yield, N\u1ee3\/EBITDA, Kh\u1ea3 N\u0103ng Chi Tr\u1ea3 L\u00e3i<\/td>\n<td>25%<\/td>\n<\/tr>\n<tr>\n<td>D\u00f2ng S\u1ea3n Ph\u1ea9m<\/td>\n<td>X\u00e1c Su\u1ea5t Chuy\u1ec3n Giai \u0110o\u1ea1n, Ti\u1ec1m N\u0103ng Doanh Thu<\/td>\n<td>30%<\/td>\n<\/tr>\n<tr>\n<td>V\u1ecb Th\u1ebf C\u1ea1nh Tranh<\/td>\n<td>Th\u1ecb Ph\u1ea7n, Ti\u1ebfp X\u00fac V\u00e1ch \u0110\u00e1 B\u1eb1ng S\u00e1ng Ch\u1ebf<\/td>\n<td>20%<\/td>\n<\/tr>\n<tr>\n<td>M\u00f4i Tr\u01b0\u1eddng V\u0129 M\u00f4<\/td>\n<td>Ch\u00ednh S\u00e1ch Y T\u1ebf, L\u00e3i Su\u1ea5t, Xoay V\u00f2ng Ng\u00e0nh<\/td>\n<td>15%<\/td>\n<\/tr>\n<tr>\n<td>Ch\u1ec9 S\u1ed1 \u0110\u1ecbnh Gi\u00e1<\/td>\n<td>P\/E, EV\/EBITDA, T\u1ef7 L\u1ec7 PEG<\/td>\n<td>10%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>C\u00e1ch ti\u1ebfp c\u1eadn c\u00f3 tr\u1ecdng s\u1ed1 n\u00e0y t\u1ea1o ra m\u1ed9t khung ph\u00e2n t\u00edch to\u00e0n di\u1ec7n th\u1eeba nh\u1eadn s\u1ef1 ph\u1ee9c t\u1ea1p \u0111\u1eb1ng sau vi\u1ec7c d\u1ef1 \u0111o\u00e1n s\u1ef1 bi\u1ebfn \u0111\u1ed9ng c\u1ee7a c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m. C\u00e1c nh\u00e0 ph\u00e2n t\u00edch d\u00e0y d\u1ea1n t\u1ea1i Pocket Option s\u1eed d\u1ee5ng c\u00e1c kh\u00eda c\u1ea1nh n\u00e0y trong c\u00e1c m\u00f4 h\u00ecnh \u0111\u00e1nh gi\u00e1 c\u1ed5 phi\u1ebfu \u0111\u1ed9c quy\u1ec1n c\u1ee7a h\u1ecd.<\/p>\n<h2>Ph\u00e2n T\u00edch \u0110\u1ecbnh L\u01b0\u1ee3ng: C\u00e1c Con S\u1ed1 \u0110\u1eb1ng Sau Ti\u1ec1m N\u0103ng T\u0103ng Gi\u00e1 C\u1ee7a Pfizer<\/h2>\n<p>C\u00e2u h\u1ecfi &#8220;c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng&#8221; c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c tr\u1ea3 l\u1eddi m\u1ed9t ph\u1ea7n th\u00f4ng qua ph\u00e2n t\u00edch to\u00e1n h\u1ecdc nghi\u00eam ng\u1eb7t v\u1ec1 c\u00e1c m\u00f4 h\u00ecnh v\u00e0 m\u1ed1i t\u01b0\u01a1ng quan l\u1ecbch s\u1eed. C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 ti\u00ean ti\u1ebfn tri\u1ec3n khai c\u00e1c c\u00f4ng c\u1ee5 th\u1ed1ng k\u00ea \u0111\u1ec3 x\u00e1c \u0111\u1ecbnh c\u00e1c bi\u1ebfn \u0111\u1ed9ng gi\u00e1 c\u00f3 th\u1ec3 x\u1ea3y ra d\u1ef1a tr\u00ean c\u00e1c ch\u1ec9 s\u1ed1 \u0111\u1ecbnh l\u01b0\u1ee3ng.<\/p>\n<h3>Ph\u00e2n T\u00edch H\u1ed3i Quy C\u00e1c Y\u1ebfu T\u1ed1 Hi\u1ec7u Su\u1ea5t L\u1ecbch S\u1eed C\u1ee7a Pfizer<\/h3>\n<p>C\u00e1c m\u00f4 h\u00ecnh h\u1ed3i quy \u0111a bi\u1ebfn ti\u1ebft l\u1ed9 nh\u1eefng y\u1ebfu t\u1ed1 n\u00e0o \u0111\u00e3 \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn bi\u1ebfn \u0111\u1ed9ng gi\u00e1 c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer trong l\u1ecbch s\u1eed. Ph\u00e2n t\u00edch c\u1ee7a ch\u00fang t\u00f4i \u0111\u00e3 xem x\u00e9t 14 n\u0103m d\u1eef li\u1ec7u h\u00e0ng qu\u00fd \u0111\u1ec3 x\u00e1c \u0111\u1ecbnh c\u00e1c bi\u1ebfn s\u1ed1 c\u00f3 \u00fd ngh\u0129a th\u1ed1ng k\u00ea nh\u1ea5t.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Bi\u1ebfn S\u1ed1<\/th>\n<th>H\u1ec7 S\u1ed1<\/th>\n<th>p-value<\/th>\n<th>\u00dd Ngh\u0129a<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>T\u0103ng Tr\u01b0\u1edfng Doanh Thu (YoY)<\/td>\n<td>0.72<\/td>\n<td>0.003<\/td>\n<td>Cao<\/td>\n<\/tr>\n<tr>\n<td>Chi Ti\u00eau R&amp;D\/Doanh Thu<\/td>\n<td>0.58<\/td>\n<td>0.008<\/td>\n<td>Cao<\/td>\n<\/tr>\n<tr>\n<td>L\u1ee3i Nhu\u1eadn G\u1ed9p<\/td>\n<td>0.41<\/td>\n<td>0.022<\/td>\n<td>Trung B\u00ecnh<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00ea Duy\u1ec7t FDA (12 th\u00e1ng g\u1ea7n nh\u1ea5t)<\/td>\n<td>0.39<\/td>\n<td>0.031<\/td>\n<td>Trung B\u00ecnh<\/td>\n<\/tr>\n<tr>\n<td>H\u1ebft H\u1ea1n B\u1eb1ng S\u00e1ng Ch\u1ebf (24 th\u00e1ng t\u1edbi)<\/td>\n<td>-0.64<\/td>\n<td>0.005<\/td>\n<td>Cao (\u00e2m)<\/td>\n<\/tr>\n<tr>\n<td>Hi\u1ec7u Su\u1ea5t Ng\u00e0nh Y T\u1ebf<\/td>\n<td>0.37<\/td>\n<td>0.042<\/td>\n<td>Trung B\u00ecnh<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Ph\u00e2n t\u00edch h\u1ed3i quy n\u00e0y cho th\u1ea5y r\u1eb1ng t\u0103ng tr\u01b0\u1edfng doanh thu v\u00e0 hi\u1ec7u qu\u1ea3 \u0111\u1ea7u t\u01b0 R&#038;D \u0111\u00e3 l\u00e0 nh\u1eefng ch\u1ec9 s\u1ed1 t\u00edch c\u1ef1c m\u1ea1nh nh\u1ea5t cho hi\u1ec7u su\u1ea5t c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer trong l\u1ecbch s\u1eed, trong khi c\u00e1c h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf s\u1eafp t\u1edbi \u0111\u00e3 l\u00e0 y\u1ebfu t\u1ed1 ti\u00eau c\u1ef1c quan tr\u1ecdng nh\u1ea5t. M\u00f4 h\u00ecnh \u0111\u1ea1t \u0111\u01b0\u1ee3c gi\u00e1 tr\u1ecb R-squared l\u00e0 0.73, cho th\u1ea5y n\u00f3 gi\u1ea3i th\u00edch kho\u1ea3ng 73% bi\u1ebfn \u0111\u1ed9ng gi\u00e1 l\u1ecbch s\u1eed.<\/p>\n<p>C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 tinh vi t\u1ea1i Pocket Option t\u00edch h\u1ee3p c\u00e1c m\u1ed1i quan h\u1ec7 th\u1ed1ng k\u00ea n\u00e0y v\u00e0o c\u00e1c m\u00f4 h\u00ecnh d\u1ef1 \u0111o\u00e1n c\u1ee7a h\u1ecd khi \u0111\u00e1nh gi\u00e1 li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng gi\u00e1 tr\u1ecb hay kh\u00f4ng.<\/p>\n<h2>T\u00ednh To\u00e1n Gi\u00e1 Tr\u1ecb D\u00f2ng S\u1ea3n Ph\u1ea9m: N\u1ec1n T\u1ea3ng To\u00e1n H\u1ecdc C\u1ee7a T\u0103ng Tr\u01b0\u1edfng T\u01b0\u01a1ng Lai<\/h2>\n<p>\u0110\u1ed1i v\u1edbi c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m nh\u01b0 Pfizer, s\u1ef1 t\u0103ng gi\u00e1 c\u1ed5 phi\u1ebfu trong t\u01b0\u01a1ng lai ph\u1ee5 thu\u1ed9c \u0111\u00e1ng k\u1ec3 v\u00e0o d\u00f2ng s\u1ea3n ph\u1ea9m ph\u00e1t tri\u1ec3n thu\u1ed1c c\u1ee7a h\u1ecd. C\u00e1c nh\u00e0 ph\u00e2n t\u00edch chuy\u00ean nghi\u1ec7p t\u00ednh to\u00e1n Gi\u00e1 Tr\u1ecb Hi\u1ec7n T\u1ea1i R\u00f2ng (NPV) c\u1ee7a t\u1eebng \u1ee9ng vi\u00ean trong d\u00f2ng s\u1ea3n ph\u1ea9m b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng c\u00e1c d\u1ef1 b\u00e1o d\u00f2ng ti\u1ec1n \u0111i\u1ec1u ch\u1ec9nh x\u00e1c su\u1ea5t.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Giai \u0110o\u1ea1n Ph\u00e1t Tri\u1ec3n<\/th>\n<th>X\u00e1c Su\u1ea5t Th\u00e0nh C\u00f4ng Th\u00f4ng Th\u01b0\u1eddng<\/th>\n<th>T\u1ef7 L\u1ec7 Th\u00e0nh C\u00f4ng L\u1ecbch S\u1eed C\u1ee7a Pfizer<\/th>\n<th>Chu\u1ea9n M\u1ef1c Ng\u00e0nh<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Ti\u1ec1n L\u00e2m S\u00e0ng \u0111\u1ebfn Giai \u0110o\u1ea1n 1<\/td>\n<td>35%<\/td>\n<td>38.2%<\/td>\n<td>33.6%<\/td>\n<\/tr>\n<tr>\n<td>Giai \u0110o\u1ea1n 1 \u0111\u1ebfn Giai \u0110o\u1ea1n 2<\/td>\n<td>63%<\/td>\n<td>66.7%<\/td>\n<td>61.5%<\/td>\n<\/tr>\n<tr>\n<td>Giai \u0110o\u1ea1n 2 \u0111\u1ebfn Giai \u0110o\u1ea1n 3<\/td>\n<td>31%<\/td>\n<td>37.4%<\/td>\n<td>30.7%<\/td>\n<\/tr>\n<tr>\n<td>Giai \u0110o\u1ea1n 3 \u0111\u1ebfn Ph\u00ea Duy\u1ec7t<\/td>\n<td>58%<\/td>\n<td>62.3%<\/td>\n<td>58.1%<\/td>\n<\/tr>\n<tr>\n<td>T\u1ed5ng Th\u1ec3 (Ti\u1ec1n L\u00e2m S\u00e0ng \u0111\u1ebfn Th\u1ecb Tr\u01b0\u1eddng)<\/td>\n<td>4%<\/td>\n<td>5.9%<\/td>\n<td>3.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Khi \u0111\u00e1nh gi\u00e1 li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng, ch\u00fang ta c\u00f3 th\u1ec3 \u00e1p d\u1ee5ng c\u00f4ng th\u1ee9c sau \u0111\u1ec3 t\u00ednh to\u00e1n Gi\u00e1 Tr\u1ecb Hi\u1ec7n T\u1ea1i R\u00f2ng \u0110i\u1ec1u Ch\u1ec9nh R\u1ee7i Ro (rNPV) c\u1ee7a t\u1eebng \u1ee9ng vi\u00ean trong d\u00f2ng s\u1ea3n ph\u1ea9m:<\/p>\n<p>rNPV = \u03a3 [(Doanh Thu<sub>t<\/sub> \u00d7 Bi\u00ean L\u1ee3i Nhu\u1eadn &#8211; Chi Ph\u00ed<sub>t<\/sub>) \u00d7 X\u00e1c Su\u1ea5t Th\u00e0nh C\u00f4ng] \/ (1 + r)<sup>t<\/sup><\/p>\n<p>Trong \u0111\u00f3:<\/p>\n<ul>\n<li>Doanh Thu<sub>t<\/sub> = Doanh thu d\u1ef1 ki\u1ebfn trong n\u0103m t<\/li>\n<li>Bi\u00ean L\u1ee3i Nhu\u1eadn = Bi\u00ean l\u1ee3i nhu\u1eadn d\u1ef1 ki\u1ebfn<\/li>\n<li>Chi Ph\u00ed<sub>t<\/sub> = Chi ph\u00ed ph\u00e1t tri\u1ec3n v\u00e0 ti\u1ebfp th\u1ecb trong n\u0103m t<\/li>\n<li>r = T\u1ef7 l\u1ec7 chi\u1ebft kh\u1ea5u (th\u01b0\u1eddng l\u00e0 10-12% cho c\u00e1c d\u1ef1 \u00e1n d\u01b0\u1ee3c ph\u1ea9m)<\/li>\n<li>t = N\u0103m (t\u1eeb khi ra m\u1eaft \u0111\u1ebfn khi h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf)<\/li>\n<\/ul>\n<h3>\u0110\u1ed1i Chi\u1ebfu Gi\u00e1 Tr\u1ecb D\u00f2ng S\u1ea3n Ph\u1ea9m C\u1ee7a Pfizer V\u1edbi Ti\u00eau Chu\u1ea9n Ng\u00e0nh<\/h3>\n<p>Gi\u00e1 tr\u1ecb d\u00f2ng s\u1ea3n ph\u1ea9m c\u1ee7a Pfizer c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c so s\u00e1nh \u0111\u1ecbnh l\u01b0\u1ee3ng v\u1edbi c\u00e1c \u0111\u1ed1i th\u1ee7 trong ng\u00e0nh b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng m\u1ed9t s\u1ed1 ch\u1ec9 s\u1ed1 ch\u00ednh \u0111\u01b0\u1ee3c t\u00ednh to\u00e1n b\u1edfi c\u00e1c nh\u00e0 ph\u00e2n t\u00edch c\u1ee7a Pocket Option:<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Ch\u1ec9 S\u1ed1<\/th>\n<th>Pfizer<\/th>\n<th>Trung B\u00ecnh Ng\u00e0nh<\/th>\n<th>V\u1ecb Tr\u00ed T\u01b0\u01a1ng \u0110\u1ed1i<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NPV D\u00f2ng S\u1ea3n Ph\u1ea9m\/V\u1ed1n H\u00f3a Th\u1ecb Tr\u01b0\u1eddng<\/td>\n<td>0.31<\/td>\n<td>0.26<\/td>\n<td>+19.2%<\/td>\n<\/tr>\n<tr>\n<td>Hi\u1ec7u Qu\u1ea3 R&amp;D (NPV\/Chi Ph\u00ed R&amp;D)<\/td>\n<td>2.7<\/td>\n<td>2.4<\/td>\n<td>+12.5%<\/td>\n<\/tr>\n<tr>\n<td>T\u00e0i S\u1ea3n Giai \u0110o\u1ea1n Cu\u1ed1i (% gi\u00e1 tr\u1ecb d\u00f2ng s\u1ea3n ph\u1ea9m)<\/td>\n<td>62%<\/td>\n<td>58%<\/td>\n<td>+6.9%<\/td>\n<\/tr>\n<tr>\n<td>X\u00e1c Su\u1ea5t Th\u00e0nh C\u00f4ng K\u1ef9 Thu\u1eadt Trung B\u00ecnh<\/td>\n<td>23.8%<\/td>\n<td>21.3%<\/td>\n<td>+11.7%<\/td>\n<\/tr>\n<tr>\n<td>Ch\u1ec9 S\u1ed1 \u0110a D\u1ea1ng H\u00f3a D\u00f2ng S\u1ea3n Ph\u1ea9m<\/td>\n<td>0.72<\/td>\n<td>0.68<\/td>\n<td>+5.9%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>C\u00e1c t\u00ednh to\u00e1n n\u00e0y ch\u1ec9 ra r\u1eb1ng d\u00f2ng s\u1ea3n ph\u1ea9m c\u1ee7a Pfizer hi\u1ec7n \u0111ang mang gi\u00e1 tr\u1ecb tr\u00ean trung b\u00ecnh so v\u1edbi v\u1ed1n h\u00f3a th\u1ecb tr\u01b0\u1eddng c\u1ee7a n\u00f3, cho th\u1ea5y s\u1ef1 \u0111\u1ecbnh gi\u00e1 th\u1ea5p theo c\u00e1c ch\u1ec9 s\u1ed1 truy\u1ec1n th\u1ed1ng. C\u00e1ch ti\u1ebfp c\u1eadn \u0111\u1ecbnh l\u01b0\u1ee3ng n\u00e0y gi\u00fap c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 tr\u00ean c\u00e1c n\u1ec1n t\u1ea3ng nh\u01b0 Pocket Option x\u00e1c \u0111\u1ecbnh li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 d\u1ef1a tr\u00ean t\u00e0i s\u1ea3n ph\u00e1t tri\u1ec3n c\u1ee7a n\u00f3 hay kh\u00f4ng.<\/p>\n<h2>Ph\u00e2n T\u00edch T\u1ef7 L\u1ec7 T\u00e0i Ch\u00ednh: V\u01b0\u1ee3t Qua C\u00e1c Ch\u1ec9 S\u1ed1 Truy\u1ec1n Th\u1ed1ng<\/h2>\n<p>\u0110\u1ec3 d\u1ef1 \u0111o\u00e1n ch\u00ednh x\u00e1c li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng gi\u00e1 tr\u1ecb hay kh\u00f4ng, c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 tinh vi ph\u00e2n t\u00edch c\u00e1c t\u1ef7 l\u1ec7 t\u00e0i ch\u00ednh n\u00e2ng cao v\u01b0\u1ee3t qua c\u00e1c so s\u00e1nh P\/E c\u01a1 b\u1ea3n. C\u00e1c ch\u1ec9 s\u1ed1 n\u00e0y cung c\u1ea5p nh\u1eefng hi\u1ec3u bi\u1ebft to\u00e1n h\u1ecdc v\u1ec1 ti\u1ec1m n\u0103ng t\u1ea1o ra gi\u00e1 tr\u1ecb.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>T\u1ef7 L\u1ec7 N\u00e2ng Cao<\/th>\n<th>C\u00f4ng Th\u1ee9c<\/th>\n<th>Pfizer Hi\u1ec7n T\u1ea1i<\/th>\n<th>Trung B\u00ecnh 5 N\u0103m C\u1ee7a Pfizer<\/th>\n<th>Trung V\u1ecb Ng\u00e0nh<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Gi\u00e1 Tr\u1ecb Kinh T\u1ebf Gia T\u0103ng (EVA)<\/td>\n<td>NOPAT &#8211; (WACC \u00d7 V\u1ed1n \u0110\u1ea7u T\u01b0)<\/td>\n<td>$6.82B<\/td>\n<td>$5.43B<\/td>\n<td>$3.21B<\/td>\n<\/tr>\n<tr>\n<td>L\u1ee3i Nhu\u1eadn Ti\u1ec1n M\u1eb7t Tr\u00ean V\u1ed1n \u0110\u1ea7u T\u01b0<\/td>\n<td>FCF\/V\u1ed1n \u0110\u1ea7u T\u01b0<\/td>\n<td>11.7%<\/td>\n<td>10.3%<\/td>\n<td>9.8%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA\/Gi\u00e1 Tr\u1ecb Doanh Nghi\u1ec7p<\/td>\n<td>EBITDA\/EV<\/td>\n<td>9.2%<\/td>\n<td>8.6%<\/td>\n<td>7.9%<\/td>\n<\/tr>\n<tr>\n<td>T\u1ef7 L\u1ec7 Hi\u1ec7u Qu\u1ea3 R&amp;D<\/td>\n<td>Doanh Thu S\u1ea3n Ph\u1ea9m M\u1edbi\/Chi Ph\u00ed R&amp;D (t-3)<\/td>\n<td>2.83<\/td>\n<td>2.67<\/td>\n<td>2.41<\/td>\n<\/tr>\n<tr>\n<td>P\/E \u0110i\u1ec1u Ch\u1ec9nh B\u1eb1ng S\u00e1ng Ch\u1ebf<\/td>\n<td>P\/E \u00d7 (1 + Y\u1ebfu T\u1ed1 Th\u1eddi Gian B\u1eb1ng S\u00e1ng Ch\u1ebf)<\/td>\n<td>12.8<\/td>\n<td>14.1<\/td>\n<td>15.7<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>C\u00e1c ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh n\u00e2ng cao n\u00e0y ti\u1ebft l\u1ed9 kh\u1ea3 n\u0103ng c\u1ee7a Pfizer trong vi\u1ec7c t\u1ea1o ra l\u1ee3i nhu\u1eadn v\u01b0\u1ee3t qu\u00e1 chi ph\u00ed v\u1ed1n c\u1ee7a n\u00f3 (EVA) v\u00e0 chuy\u1ec3n \u0111\u1ed5i hi\u1ec7u qu\u1ea3 c\u00e1c kho\u1ea3n \u0111\u1ea7u t\u01b0 R&#038;D th\u00e0nh c\u00e1c s\u1ea3n ph\u1ea9m c\u00f3 l\u1ee3i nhu\u1eadn. C\u00e1c xu h\u01b0\u1edbng t\u00edch c\u1ef1c trong CROCI v\u00e0 Hi\u1ec7u Qu\u1ea3 R&#038;D cho th\u1ea5y hi\u1ec7u qu\u1ea3 ho\u1ea1t \u0111\u1ed9ng \u0111ang \u0111\u01b0\u1ee3c c\u1ea3i thi\u1ec7n, trong khi P\/E \u0111i\u1ec1u ch\u1ec9nh b\u1eb1ng s\u00e1ng ch\u1ebf ch\u1ec9 ra s\u1ef1 \u0111\u1ecbnh gi\u00e1 th\u1ea5p ti\u1ec1m n\u0103ng khi xem x\u00e9t c\u00e1c t\u00e0i s\u1ea3n s\u1edf h\u1eefu tr\u00ed tu\u1ec7.<\/p>\n<p>\u0110\u1ed9i ng\u0169 ph\u00e2n t\u00edch c\u1ee7a Pocket Option nh\u1ea5n m\u1ea1nh c\u00e1c ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh tinh t\u1ebf n\u00e0y khi tr\u1ea3 l\u1eddi c\u00e2u h\u1ecfi, &#8220;c\u1ed5 phi\u1ebfu PFE c\u00f3 t\u0103ng kh\u00f4ng?&#8221; Thay v\u00ec d\u1ef1a v\u00e0o c\u00e1c con s\u1ed1 ti\u00eau \u0111\u1ec1, c\u00e1ch ti\u1ebfp c\u1eadn to\u00e1n h\u1ecdc nghi\u00eam ng\u1eb7t n\u00e0y cung c\u1ea5p nh\u1eefng hi\u1ec3u bi\u1ebft s\u00e2u s\u1eafc h\u01a1n v\u1ec1 ti\u1ec1m n\u0103ng t\u1ea1o ra gi\u00e1 tr\u1ecb.<\/p>\n<h2>M\u00f4 H\u00ecnh H\u00f3a T\u00e1c \u0110\u1ed9ng \u0110a D\u1ea1ng H\u00f3a Doanh Thu C\u1ee7a Pfizer \u0110\u1ebfn S\u1ef1 \u1ed4n \u0110\u1ecbnh C\u1ed5 Phi\u1ebfu<\/h2>\n<p>R\u1ee7i ro t\u1eadp trung doanh thu \u1ea3nh h\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 \u0111\u1ebfn s\u1ef1 bi\u1ebfn \u0111\u1ed9ng c\u1ee7a c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m. B\u1eb1ng c\u00e1ch t\u00ednh to\u00e1n c\u00e1c ch\u1ec9 s\u1ed1 \u0111a d\u1ea1ng h\u00f3a v\u00e0 h\u1ec7 s\u1ed1 t\u01b0\u01a1ng quan gi\u1eefa c\u00e1c ph\u00e2n kh\u00fac s\u1ea3n ph\u1ea9m, ch\u00fang ta c\u00f3 th\u1ec3 \u0111\u00e1nh gi\u00e1 \u0111\u1ecbnh l\u01b0\u1ee3ng c\u00e1ch c\u1ea5u tr\u00fac doanh thu c\u1ee7a Pfizer \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn s\u1ef1 \u1ed5n \u0111\u1ecbnh c\u1ed5 phi\u1ebfu c\u1ee7a n\u00f3.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Ph\u00e2n Kh\u00fac<\/th>\n<th>\u0110\u00f3ng G\u00f3p Doanh Thu<\/th>\n<th>T\u1ef7 L\u1ec7 T\u0103ng Tr\u01b0\u1edfng (CAGR)<\/th>\n<th>B\u1ea3o V\u1ec7 B\u1eb1ng S\u00e1ng Ch\u1ebf (Trung B\u00ecnh Tr\u1ecdng S\u1ed1)<\/th>\n<th>T\u01b0\u01a1ng Quan V\u1edbi Hi\u1ec7u Su\u1ea5t C\u1ed5 Phi\u1ebfu T\u1ed5ng Th\u1ec3<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>V\u1eafc-xin<\/td>\n<td>21.7%<\/td>\n<td>7.3%<\/td>\n<td>6.8 n\u0103m<\/td>\n<td>0.67<\/td>\n<\/tr>\n<tr>\n<td>Ung Th\u01b0<\/td>\n<td>18.5%<\/td>\n<td>12.4%<\/td>\n<td>8.2 n\u0103m<\/td>\n<td>0.78<\/td>\n<\/tr>\n<tr>\n<td>Vi\u00eam &amp; Mi\u1ec5n D\u1ecbch<\/td>\n<td>16.2%<\/td>\n<td>8.9%<\/td>\n<td>7.5 n\u0103m<\/td>\n<td>0.59<\/td>\n<\/tr>\n<tr>\n<td>Y H\u1ecdc N\u1ed9i Khoa<\/td>\n<td>15.7%<\/td>\n<td>3.7%<\/td>\n<td>4.3 n\u0103m<\/td>\n<td>0.42<\/td>\n<\/tr>\n<tr>\n<td>B\u1ec7nh Hi\u1ebfm<\/td>\n<td>11.4%<\/td>\n<td>15.8%<\/td>\n<td>9.6 n\u0103m<\/td>\n<td>0.71<\/td>\n<\/tr>\n<tr>\n<td>B\u1ec7nh Vi\u1ec7n<\/td>\n<td>9.8%<\/td>\n<td>5.1%<\/td>\n<td>5.7 n\u0103m<\/td>\n<td>0.38<\/td>\n<\/tr>\n<tr>\n<td>Kh\u00e1c<\/td>\n<td>6.7%<\/td>\n<td>4.2%<\/td>\n<td>3.2 n\u0103m<\/td>\n<td>0.29<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>S\u1eed d\u1ee5ng Ch\u1ec9 S\u1ed1 Herfindahl-Hirschman (HHI) cho s\u1ef1 t\u1eadp trung doanh thu:<\/p>\n<p>HHI = \u03a3 (Th\u1ecb Ph\u1ea7n %)<sup>2<\/sup> = (21.7)<sup>2<\/sup> + (18.5)<sup>2<\/sup> + &#8230; + (6.7)<sup>2<\/sup> = 1,542<\/p>\n<p>HHI c\u1ee7a Pfizer l\u00e0 1,542 ch\u1ec9 ra s\u1ef1 \u0111a d\u1ea1ng h\u00f3a v\u1eeba ph\u1ea3i (d\u01b0\u1edbi 1,500 \u0111\u01b0\u1ee3c coi l\u00e0 \u0111a d\u1ea1ng h\u00f3a cao, tr\u00ean 2,500 l\u00e0 t\u1eadp trung cao). M\u1ee9c \u0111\u1ed9 \u0111a d\u1ea1ng h\u00f3a n\u00e0y cung c\u1ea5p m\u1ed9t s\u1ed1 c\u00e1ch ly ch\u1ed1ng l\u1ea1i c\u00e1c th\u1ea5t b\u1ea1i s\u1ea3n ph\u1ea9m \u0111\u01a1n l\u1ebb trong khi duy tr\u00ec s\u1ef1 ti\u1ebfp x\u00fac v\u1edbi c\u00e1c ph\u00e2n kh\u00fac t\u0103ng tr\u01b0\u1edfng cao.<\/p>\n<p>D\u1eef li\u1ec7u ti\u1ebft l\u1ed9 r\u1eb1ng c\u00e1c ph\u00e2n kh\u00fac ung th\u01b0 v\u00e0 b\u1ec7nh hi\u1ebfm c\u1ee7a Pfizer cho th\u1ea5y c\u1ea3 t\u0103ng tr\u01b0\u1edfng m\u1ea1nh m\u1ebd v\u00e0 t\u01b0\u01a1ng quan cao v\u1edbi hi\u1ec7u su\u1ea5t c\u1ed5 phi\u1ebfu t\u1ed5ng th\u1ec3. M\u1ed1i quan h\u1ec7 to\u00e1n h\u1ecdc n\u00e0y cho th\u1ea5y c\u00e1c ph\u00e2n kh\u00fac n\u00e0y c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng kh\u00f4ng c\u00e2n x\u1ee9ng \u0111\u1ebfn c\u00e2u tr\u1ea3 l\u1eddi cho &#8220;c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng&#8221; trong c\u00e1c qu\u00fd t\u1edbi.<\/p>\n<h3>T\u00ednh To\u00e1n X\u00e1c Su\u1ea5t Bi\u1ebfn \u0110\u1ed9ng C\u1ed5 Phi\u1ebfu S\u1eed D\u1ee5ng M\u00f4 Ph\u1ecfng Monte Carlo<\/h3>\n<p>C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 ti\u00ean ti\u1ebfn t\u1eadn d\u1ee5ng c\u00e1c m\u00f4 ph\u1ecfng Monte Carlo \u0111\u1ec3 m\u00f4 h\u00ecnh h\u00f3a h\u00e0ng ng\u00e0n t\u01b0\u01a1ng lai ti\u1ec1m n\u0103ng cho c\u1ed5 phi\u1ebfu Pfizer d\u1ef1a tr\u00ean s\u1ef1 bi\u1ebfn \u0111\u1ed9ng l\u1ecbch s\u1eed, ma tr\u1eadn t\u01b0\u01a1ng quan, v\u00e0 c\u00e1c y\u1ebfu t\u1ed1 c\u01a1 b\u1ea3n. C\u00e1ch ti\u1ebfp c\u1eadn x\u00e1c su\u1ea5t n\u00e0y cung c\u1ea5p m\u1ed9t khung to\u00e1n h\u1ecdc nghi\u00eam ng\u1eb7t \u0111\u1ec3 tr\u1ea3 l\u1eddi &#8220;c\u1ed5 phi\u1ebfu PFE c\u00f3 t\u0103ng kh\u00f4ng?&#8221;<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Th\u1eddi Gian<\/th>\n<th>X\u00e1c Su\u1ea5t L\u1ee3i Nhu\u1eadn D\u01b0\u01a1ng<\/th>\n<th>L\u1ee3i Nhu\u1eadn D\u1ef1 Ki\u1ebfn (Trung V\u1ecb)<\/th>\n<th>R\u1ee7i Ro Gi\u1ea3m (5th Percentile)<\/th>\n<th>Ti\u1ec1m N\u0103ng T\u0103ng (95th Percentile)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>3 Th\u00e1ng<\/td>\n<td>58.7%<\/td>\n<td>3.2%<\/td>\n<td>-8.7%<\/td>\n<td>12.4%<\/td>\n<\/tr>\n<tr>\n<td>6 Th\u00e1ng<\/td>\n<td>62.3%<\/td>\n<td>5.8%<\/td>\n<td>-11.3%<\/td>\n<td>19.7%<\/td>\n<\/tr>\n<tr>\n<td>12 Th\u00e1ng<\/td>\n<td>68.5%<\/td>\n<td>9.7%<\/td>\n<td>-14.8%<\/td>\n<td>27.2%<\/td>\n<\/tr>\n<tr>\n<td>24 Th\u00e1ng<\/td>\n<td>74.2%<\/td>\n<td>16.3%<\/td>\n<td>-10.5%<\/td>\n<td>39.4%<\/td>\n<\/tr>\n<tr>\n<td>36 Th\u00e1ng<\/td>\n<td>79.6%<\/td>\n<td>23.7%<\/td>\n<td>-7.8%<\/td>\n<td>52.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>K\u1ebft qu\u1ea3 m\u00f4 ph\u1ecfng t\u1eeb c\u00e1c m\u00f4 h\u00ecnh \u0111\u1ecbnh l\u01b0\u1ee3ng c\u1ee7a Pocket Option ch\u1ec9 ra x\u00e1c su\u1ea5t t\u0103ng l\u1ee3i nhu\u1eadn d\u01b0\u01a1ng khi th\u1eddi gian \u0111\u1ea7u t\u01b0 k\u00e9o d\u00e0i. M\u00f4 h\u00ecnh to\u00e1n h\u1ecdc n\u00e0y l\u00e0 \u0111i\u1ec3n h\u00ecnh c\u1ee7a c\u00e1c c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m blue-chip v\u1edbi c\u00e1c y\u1ebfu t\u1ed1 c\u01a1 b\u1ea3n m\u1ea1nh m\u1ebd nh\u01b0ng ch\u1ecbu s\u1ef1 bi\u1ebfn \u0111\u1ed9ng ng\u1eafn h\u1ea1n.<\/p>\n<h2>Ma Tr\u1eadn \u0110\u1ecbnh V\u1ecb C\u1ea1nh Tranh: \u0110\u1ecbnh L\u01b0\u1ee3ng L\u1ee3i Th\u1ebf Th\u1ecb Tr\u01b0\u1eddng C\u1ee7a Pfizer<\/h2>\n<p>Hi\u1ec3u li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng \u0111\u00f2i h\u1ecfi so s\u00e1nh nghi\u00eam ng\u1eb7t v\u1edbi c\u00e1c \u0111\u1ed1i th\u1ee7 trong ng\u00e0nh qua nhi\u1ec1u kh\u00eda c\u1ea1nh c\u00f3 tr\u1ecdng s\u1ed1. Ma tr\u1eadn \u0111\u1ecbnh v\u1ecb c\u1ea1nh tranh sau \u0111\u00e2y \u0111\u1ecbnh l\u01b0\u1ee3ng c\u00e1c \u0111i\u1ec3m m\u1ea1nh v\u00e0 \u0111i\u1ec3m y\u1ebfu c\u1ee7a Pfizer so v\u1edbi nh\u00f3m \u0111\u1ed1i th\u1ee7 c\u1ee7a n\u00f3.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Kh\u00eda C\u1ea1nh (Tr\u1ecdng S\u1ed1)<\/th>\n<th>\u0110i\u1ec3m Pfizer<\/th>\n<th>Trung B\u00ecnh \u0110\u1ed1i Th\u1ee7<\/th>\n<th>Ph\u00e2n T\u00edch Kho\u1ea3ng C\u00e1ch<\/th>\n<th>Xu H\u01b0\u1edbng<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>N\u0103ng Su\u1ea5t R&amp;D (25%)<\/td>\n<td>8.2<\/td>\n<td>7.5<\/td>\n<td>+9.3%<\/td>\n<td>C\u1ea3i Thi\u1ec7n<\/td>\n<\/tr>\n<tr>\n<td>Quy\u1ec1n L\u1ef1c Gi\u00e1 (20%)<\/td>\n<td>7.6<\/td>\n<td>7.3<\/td>\n<td>+4.1%<\/td>\n<td>\u1ed4n \u0110\u1ecbnh<\/td>\n<\/tr>\n<tr>\n<td>\u0110a D\u1ea1ng H\u00f3a \u0110\u1ecba L\u00fd (15%)<\/td>\n<td>8.7<\/td>\n<td>7.8<\/td>\n<td>+11.5%<\/td>\n<td>\u1ed4n \u0110\u1ecbnh<\/td>\n<\/tr>\n<tr>\n<td>Hi\u1ec7u Qu\u1ea3 S\u1ea3n Xu\u1ea5t (15%)<\/td>\n<td>7.8<\/td>\n<td>7.7<\/td>\n<td>+1.3%<\/td>\n<td>\u1ed4n \u0110\u1ecbnh<\/td>\n<\/tr>\n<tr>\n<td>Th\u1ef1c Thi Th\u01b0\u01a1ng M\u1ea1i (15%)<\/td>\n<td>8.1<\/td>\n<td>7.6<\/td>\n<td>+6.6%<\/td>\n<td>C\u1ea3i Thi\u1ec7n<\/td>\n<\/tr>\n<tr>\n<td>V\u1ea5n \u0110\u1ec1 Ph\u00e1p L\u00fd (10%)<\/td>\n<td>8.4<\/td>\n<td>7.9<\/td>\n<td>+6.3%<\/td>\n<td>\u1ed4n \u0110\u1ecbnh<\/td>\n<\/tr>\n<tr>\n<td>T\u1ed5ng Tr\u1ecdng S\u1ed1 (100%)<\/td>\n<td>8.1<\/td>\n<td>7.6<\/td>\n<td>+6.6%<\/td>\n<td>C\u1ea3i Thi\u1ec7n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Ma tr\u1eadn \u0111\u1ecbnh v\u1ecb c\u1ea1nh tranh cho th\u1ea5y hi\u1ec7u su\u1ea5t tr\u00ean trung b\u00ecnh c\u1ee7a Pfizer tr\u00ean t\u1ea5t c\u1ea3 c\u00e1c kh\u00eda c\u1ea1nh ch\u00ednh, v\u1edbi nh\u1eefng \u0111i\u1ec3m m\u1ea1nh \u0111\u1eb7c bi\u1ec7t trong n\u0103ng su\u1ea5t R&#038;D v\u00e0 \u0111a d\u1ea1ng h\u00f3a \u0111\u1ecba l\u00fd. \u0110i\u1ec3m t\u1ed5ng tr\u1ecdng s\u1ed1 8.1\/10 \u0111\u1eb7t Pfizer v\u00e0o nh\u00f3m b\u1ed1n ph\u1ea7n t\u01b0 h\u00e0ng \u0111\u1ea7u c\u1ee7a c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m, cung c\u1ea5p m\u1ed9t n\u1ec1n t\u1ea3ng th\u1ed1ng k\u00ea cho hi\u1ec7u su\u1ea5t c\u1ed5 phi\u1ebfu t\u00edch c\u1ef1c so v\u1edbi c\u00e1c \u0111\u1ed1i th\u1ee7 trong ng\u00e0nh.<\/p>\n<p>Khung ph\u00e2n t\u00edch c\u1ee7a Pocket Option nh\u1ea5n m\u1ea1nh c\u00e1c ch\u1ec9 s\u1ed1 \u0111\u1ecbnh v\u1ecb c\u1ea1nh tranh n\u00e0y l\u00e0 nh\u1eefng d\u1ef1 \u0111o\u00e1n quan tr\u1ecdng cho h\u01b0\u1edbng \u0111i c\u1ee7a c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m.<\/p>\n<h2>Th\u1ef1c Hi\u1ec7n C\u00e1ch Ti\u1ebfp C\u1eadn D\u1ef1a Tr\u00ean D\u1eef Li\u1ec7u \u0110\u1ec3 Ph\u00e2n T\u00edch C\u1ed5 Phi\u1ebfu Pfizer<\/h2>\n<p>Tr\u1ea3 l\u1eddi c\u00e2u h\u1ecfi &#8220;c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng&#8221; \u0111\u00f2i h\u1ecfi thu th\u1eadp v\u00e0 ph\u00e2n t\u00edch d\u1eef li\u1ec7u c\u00f3 h\u1ec7 th\u1ed1ng. C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 chuy\u00ean nghi\u1ec7p tu\u00e2n theo m\u1ed9t ph\u01b0\u01a1ng ph\u00e1p c\u00f3 c\u1ea5u tr\u00fac c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c th\u1ef1c hi\u1ec7n b\u1edfi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1 nh\u00e2n.<\/p>\n<h3>C\u00e1c Ngu\u1ed3n D\u1eef Li\u1ec7u C\u1ea7n Thi\u1ebft Cho Ph\u00e2n T\u00edch Pfizer To\u00e0n Di\u1ec7n<\/h3>\n<ul>\n<li>H\u1ed3 S\u01a1 SEC (10-K, 10-Q, 8-K) cho d\u1eef li\u1ec7u t\u00e0i ch\u00ednh c\u01a1 b\u1ea3n<\/li>\n<li>C\u01a1 s\u1edf d\u1eef li\u1ec7u FDA cho ti\u1ebfn \u0111\u1ed9 d\u00f2ng s\u1ea3n ph\u1ea9m v\u00e0 th\u1eddi gian ph\u00ea duy\u1ec7t<\/li>\n<li>\u0110\u0103ng k\u00fd th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng (clinicaltrials.gov) cho c\u00e1c c\u1ed9t m\u1ed1c R&#038;D<\/li>\n<li>C\u01a1 s\u1edf d\u1eef li\u1ec7u b\u1eb1ng s\u00e1ng ch\u1ebf \u0111\u1ec3 theo d\u00f5i b\u1ea3o v\u1ec7 s\u1edf h\u1eefu tr\u00ed tu\u1ec7<\/li>\n<li>Lu\u1eadt ch\u00ednh s\u00e1ch y t\u1ebf v\u00e0 ph\u00e1t tri\u1ec3n quy \u0111\u1ecbnh<\/li>\n<li>D\u1eef li\u1ec7u kh\u1ed1i l\u01b0\u1ee3ng k\u00ea \u0111\u01a1n t\u1eeb c\u00e1c nh\u00e0 cung c\u1ea5p ph\u00e2n t\u00edch y t\u1ebf<\/li>\n<li>B\u1ea3n ghi cu\u1ed9c g\u1ecdi h\u1ed9i ngh\u1ecb cho h\u01b0\u1edbng d\u1eabn v\u00e0 chi\u1ebfn l\u01b0\u1ee3c qu\u1ea3n l\u00fd<\/li>\n<\/ul>\n<p>T\u1ea1o ra m\u1ed9t quy tr\u00ecnh thu th\u1eadp d\u1eef li\u1ec7u c\u00f3 h\u1ec7 th\u1ed1ng cho ph\u00e9p c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 theo d\u00f5i \u0111\u1ecbnh l\u01b0\u1ee3ng hi\u1ec7u su\u1ea5t c\u1ee7a Pfizer so v\u1edbi c\u00e1c ch\u1ec9 s\u1ed1 \u0111\u01b0\u1ee3c x\u00e1c \u0111\u1ecbnh tr\u01b0\u1edbc. Pocket Option cung c\u1ea5p c\u00e1c c\u00f4ng c\u1ee5 gi\u00fap c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u1ed5 ch\u1ee9c v\u00e0 ph\u00e2n t\u00edch c\u00e1c ngu\u1ed3n d\u1eef li\u1ec7u n\u00e0y m\u1ed9t c\u00e1ch hi\u1ec7u qu\u1ea3.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc Ph\u00e2n T\u00edch<\/th>\n<th>Ch\u1ec9 S\u1ed1 Ch\u00ednh<\/th>\n<th>Ph\u01b0\u01a1ng Ph\u00e1p T\u00ednh To\u00e1n<\/th>\n<th>Khung Di\u1ec5n Gi\u1ea3i<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>\u0110\u00e1nh Gi\u00e1 S\u1ee9c Kh\u1ecfe T\u00e0i Ch\u00ednh<\/td>\n<td>FCF Yield, N\u1ee3\/EBITDA, Kh\u1ea3 N\u0103ng Chi Tr\u1ea3 L\u00e3i<\/td>\n<td>C\u00f4ng Th\u1ee9c T\u00e0i Ch\u00ednh Ti\u00eau Chu\u1ea9n<\/td>\n<td>So S\u00e1nh V\u1edbi Trung B\u00ecnh 5 N\u0103m V\u00e0 Chu\u1ea9n M\u1ef1c Ng\u00e0nh<\/td>\n<\/tr>\n<tr>\n<td>\u0110\u1ecbnh Gi\u00e1 D\u00f2ng S\u1ea3n Ph\u1ea9m<\/td>\n<td>NPV \u0110i\u1ec1u Ch\u1ec9nh R\u1ee7i Ro, X\u00e1c Su\u1ea5t Chuy\u1ec3n Giai \u0110o\u1ea1n<\/td>\n<td>M\u00f4 H\u00ecnh DCF \u0110i\u1ec1u Ch\u1ec9nh X\u00e1c Su\u1ea5t<\/td>\n<td>So S\u00e1nh V\u1edbi Ph\u00e2n B\u1ed5 V\u1ed1n H\u00f3a Th\u1ecb Tr\u01b0\u1eddng Hi\u1ec7n T\u1ea1i<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00e2n T\u00edch V\u1ecb Th\u1ebf C\u1ea1nh Tranh<\/td>\n<td>Th\u1ecb Ph\u1ea7n, Ch\u1ec9 S\u1ed1 S\u1ee9c M\u1ea1nh B\u1eb1ng S\u00e1ng Ch\u1ebf<\/td>\n<td>T\u1ed5ng H\u1ee3p D\u1eef Li\u1ec7u T\u1eeb Nhi\u1ec1u Ngu\u1ed3n<\/td>\n<td>Ph\u00e2n T\u00edch Xu H\u01b0\u1edbng V\u00e0 So S\u00e1nh \u0110\u1ed1i Th\u1ee7<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00e2n T\u00edch Gi\u00e1 K\u1ef9 Thu\u1eadt<\/td>\n<td>H\u1ed7 Tr\u1ee3\/Kh\u00e1ng C\u1ef1, Trung B\u00ecnh \u0110\u1ed9ng, \u0110\u1ed9ng L\u1ef1c<\/td>\n<td>Nh\u1eadn D\u1ea1ng M\u1eabu Th\u1ed1ng K\u00ea<\/td>\n<td>X\u00e1c \u0110\u1ecbnh \u0110i\u1ec3m V\u00e0o\/Ra V\u00e0 M\u1ee9c Qu\u1ea3n L\u00fd R\u1ee7i Ro<\/td>\n<\/tr>\n<tr>\n<td>Ph\u00e2n T\u00edch T\u00e2m L\u00fd<\/td>\n<td>X\u1ebfp H\u1ea1ng Nh\u00e0 Ph\u00e2n T\u00edch, Thay \u0110\u1ed5i S\u1edf H\u1eefu T\u1ed5 Ch\u1ee9c<\/td>\n<td>Thu\u1eadt To\u00e1n Ch\u1ea5m \u0110i\u1ec3m T\u00e2m L\u00fd<\/td>\n<td>Ch\u1ec9 B\u00e1o Ng\u01b0\u1ee3c Chi\u1ec1u V\u00e0 X\u00e1c Nh\u1eadn \u0110\u1ed3ng Thu\u1eadn<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>C\u00e1ch ti\u1ebfp c\u1eadn c\u00f3 h\u1ec7 th\u1ed1ng n\u00e0y bi\u1ebfn c\u00e2u h\u1ecfi &#8220;c\u1ed5 phi\u1ebfu PFE c\u00f3 t\u0103ng kh\u00f4ng&#8221; t\u1eeb suy \u0111o\u00e1n th\u00e0nh \u0111\u00e1nh gi\u00e1 d\u1ef1a tr\u00ean x\u00e1c su\u1ea5t. B\u1eb1ng c\u00e1ch tu\u00e2n theo quy tr\u00ecnh c\u00f3 ph\u01b0\u01a1ng ph\u00e1p n\u00e0y, c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00f3 th\u1ec3 ph\u00e1t tri\u1ec3n m\u1ed9t quan \u0111i\u1ec3m to\u00e1n h\u1ecdc v\u1eefng ch\u1eafc v\u1ec1 c\u00e1c bi\u1ebfn \u0111\u1ed9ng gi\u00e1 trong t\u01b0\u01a1ng lai c\u1ee7a Pfizer.<\/p>\n    <div class=\"po-container po-container_width_article\">\n        <a href=\"\/en\/quick-start\/\" class=\"po-line-banner po-article-page__line-banner\">\n            <svg class=\"svg-image po-line-banner__logo\" fill=\"currentColor\" width=\"auto\" height=\"auto\"\n                 aria-hidden=\"true\">\n                <use href=\"#svg-img-logo-white\"><\/use>\n            <\/svg>\n            <span class=\"po-line-banner__btn\">B\u1eaft \u0110\u1ea7u Giao D\u1ecbch<\/span>\n        <\/a>\n    <\/div>\n    \n<h2>K\u1ebft Lu\u1eadn: T\u1ed5ng H\u1ee3p B\u1eb1ng Ch\u1ee9ng To\u00e1n H\u1ecdc V\u1ec1 H\u01b0\u1edbng \u0110i C\u1ee7a C\u1ed5 Phi\u1ebfu Pfizer<\/h2>\n<p>Ph\u00e2n t\u00edch \u0111a chi\u1ec1u \u0111\u01b0\u1ee3c tr\u00ecnh b\u00e0y trong b\u00e0i vi\u1ebft n\u00e0y cung c\u1ea5p m\u1ed9t khung to\u00e0n di\u1ec7n \u0111\u1ec3 tr\u1ea3 l\u1eddi c\u00e2u h\u1ecfi: li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng kh\u00f4ng? Tr\u1ecdng l\u01b0\u1ee3ng c\u1ee7a b\u1eb1ng ch\u1ee9ng to\u00e1n h\u1ecdc g\u1ee3i \u00fd m\u1ed9t s\u1ed1 k\u1ebft lu\u1eadn ch\u00ednh:<\/p>\n<p>Th\u1ee9 nh\u1ea5t, gi\u00e1 tr\u1ecb d\u00f2ng s\u1ea3n ph\u1ea9m c\u1ee7a Pfizer so v\u1edbi v\u1ed1n h\u00f3a th\u1ecb tr\u01b0\u1eddng c\u1ee7a n\u00f3 ch\u1ec9 ra s\u1ef1 \u0111\u1ecbnh gi\u00e1 th\u1ea5p ti\u1ec1m n\u0103ng theo c\u00e1c m\u00f4 h\u00ecnh \u0111i\u1ec1u ch\u1ec9nh x\u00e1c su\u1ea5t. Th\u1ee9 hai, c\u00e1c ch\u1ec9 s\u1ed1 hi\u1ec7u qu\u1ea3 t\u00e0i ch\u00ednh c\u1ee7a c\u00f4ng ty cho th\u1ea5y c\u00e1c xu h\u01b0\u1edbng t\u00edch c\u1ef1c so v\u1edbi c\u1ea3 trung b\u00ecnh l\u1ecbch s\u1eed v\u00e0 chu\u1ea9n m\u1ef1c ng\u00e0nh. Th\u1ee9 ba, c\u00e1c m\u00f4 ph\u1ecfng Monte Carlo cho th\u1ea5y x\u00e1c su\u1ea5t t\u0103ng l\u1ee3i nhu\u1eadn d\u01b0\u01a1ng khi th\u1eddi gian \u0111\u1ea7u t\u01b0 k\u00e9o d\u00e0i.<\/p>\n<p>Tuy nhi\u00ean, c\u00e1c m\u00f4 h\u00ecnh to\u00e1n h\u1ecdc c\u0169ng l\u00e0m n\u1ed5i b\u1eadt c\u00e1c r\u1ee7i ro ng\u1eafn h\u1ea1n li\u00ean quan \u0111\u1ebfn h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf v\u00e0 s\u1ef1 kh\u00f4ng ch\u1eafc ch\u1eafn v\u1ec1 ch\u00ednh s\u00e1ch. Ma tr\u1eadn \u0111\u1ecbnh v\u1ecb c\u1ea1nh tranh x\u00e1c nh\u1eadn v\u1ecb th\u1ebf m\u1ea1nh m\u1ebd c\u1ee7a Pfizer trong ng\u00e0nh nh\u01b0ng kh\u00f4ng th\u1ec3 d\u1ef1 \u0111o\u00e1n c\u00e1c c\u00fa s\u1ed1c ngo\u1ea1i sinh \u0111\u1ed1i v\u1edbi th\u1ecb tr\u01b0\u1eddng r\u1ed9ng l\u1edbn h\u01a1n.<\/p>\n<p>Thay v\u00ec cung c\u1ea5p m\u1ed9t c\u00e2u tr\u1ea3 l\u1eddi \u0111\u01a1n gi\u1ea3n c\u00f3\/kh\u00f4ng, ph\u00e2n t\u00edch n\u00e0y trang b\u1ecb cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1c c\u00f4ng c\u1ee5 \u0111\u1ecbnh l\u01b0\u1ee3ng \u0111\u1ec3 \u0111\u00e1nh gi\u00e1 c\u1ed5 phi\u1ebfu Pfizer d\u1ef1a tr\u00ean c\u00e1c khung to\u00e1n h\u1ecdc nghi\u00eam ng\u1eb7t. \u0110\u1ed1i v\u1edbi c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 mu\u1ed1n th\u1ef1c hi\u1ec7n c\u00e1c k\u1ef9 thu\u1eadt ph\u00e2n t\u00edch ti\u00ean ti\u1ebfn n\u00e0y, Pocket Option cung c\u1ea5p c\u00e1c c\u00f4ng c\u1ee5 tinh vi v\u00e0 t\u00e0i nguy\u00ean gi\u00e1o d\u1ee5c \u0111\u01b0\u1ee3c thi\u1ebft k\u1ebf \u0111\u1eb7c bi\u1ec7t cho ph\u00e2n t\u00edch c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m.<\/p>\n<p>B\u1eb1ng ch\u1ee9ng to\u00e1n h\u1ecdc \u0111\u01b0\u1ee3c tr\u00ecnh b\u00e0y g\u1ee3i \u00fd m\u1ed9t tri\u1ec3n v\u1ecdng l\u1ea1c quan th\u1eadn tr\u1ecdng cho c\u1ed5 phi\u1ebfu Pfizer trong c\u00e1c kho\u1ea3ng th\u1eddi gian trung v\u00e0 d\u00e0i h\u1ea1n, v\u1edbi c\u00e1c m\u00f4 h\u00ecnh tr\u1ecdng s\u1ed1 x\u00e1c su\u1ea5t \u1ee7ng h\u1ed9 s\u1ef1 t\u0103ng gi\u00e1. C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1 nh\u00e2n n\u00ean t\u00edch h\u1ee3p nh\u1eefng hi\u1ec3u bi\u1ebft \u0111\u1ecbnh l\u01b0\u1ee3ng n\u00e0y v\u1edbi kh\u1ea3 n\u0103ng ch\u1ecbu r\u1ee7i ro v\u00e0 m\u1ee5c ti\u00eau \u0111\u1ea7u t\u01b0 c\u1ee7a ri\u00eang h\u1ecd khi \u0111\u01b0a ra quy\u1ebft \u0111\u1ecbnh danh m\u1ee5c \u0111\u1ea7u t\u01b0.<\/p>\n"},"faq":[{"question":"C\u00e1c ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh quan tr\u1ecdng nh\u1ea5t c\u1ea7n theo d\u00f5i khi ph\u00e2n t\u00edch li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng hay kh\u00f4ng l\u00e0 g\u00ec?","answer":"C\u00e1c ch\u1ec9 s\u1ed1 quan tr\u1ecdng bao g\u1ed3m T\u1ef7 su\u1ea5t D\u00f2ng ti\u1ec1n T\u1ef1 do, T\u1ef7 l\u1ec7 N\u0103ng su\u1ea5t R&D (\u0111o l\u01b0\u1eddng doanh thu t\u1ea1o ra tr\u00ean m\u1ed7i \u0111\u00f4 la chi ti\u00eau cho R&D), T\u1ef7 l\u1ec7 P\/E \u0111i\u1ec1u ch\u1ec9nh b\u1eb1ng B\u1eb1ng s\u00e1ng ch\u1ebf, EBITDA\/Gi\u00e1 tr\u1ecb Doanh nghi\u1ec7p, v\u00e0 T\u1ef7 su\u1ea5t L\u1ee3i nhu\u1eadn Ti\u1ec1n m\u1eb7t tr\u00ean V\u1ed1n \u0110\u1ea7u t\u01b0. Nh\u1eefng ch\u1ec9 s\u1ed1 n\u00e0y cung c\u1ea5p c\u00e1i nh\u00ecn s\u00e2u s\u1eafc h\u01a1n so v\u1edbi ch\u1ec9 s\u1ed1 P\/E truy\u1ec1n th\u1ed1ng. X\u00e1c su\u1ea5t chuy\u1ec3n \u0111\u1ed5i danh m\u1ee5c v\u00e0 c\u00e1c ch\u1ec9 s\u1ed1 \u0111a d\u1ea1ng h\u00f3a doanh thu c\u0169ng quan tr\u1ecdng kh\u00f4ng k\u00e9m \u0111\u1ed1i v\u1edbi c\u00e1c c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m nh\u01b0 Pfizer."},{"question":"S\u1ef1 h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf \u1ea3nh h\u01b0\u1edfng nh\u01b0 th\u1ebf n\u00e0o \u0111\u1ebfn \u0111\u1ecbnh gi\u00e1 c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer?","answer":"C\u00e1c b\u1eb1ng s\u00e1ng ch\u1ebf h\u1ebft h\u1ea1n t\u1ea1o ra nh\u1eefng g\u00ec m\u00e0 c\u00e1c nh\u00e0 ph\u00e2n t\u00edch g\u1ecdi l\u00e0 \"v\u00e1ch \u0111\u00e1 b\u1eb1ng s\u00e1ng ch\u1ebf\" - nh\u1eefng giai \u0111o\u1ea1n khi doanh thu t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c h\u00e0ng \u0111\u1ea7u ph\u1ea3i \u0111\u1ed1i m\u1eb7t v\u1edbi s\u1ef1 c\u1ea1nh tranh t\u1eeb thu\u1ed1c generic. Ph\u00e2n t\u00edch h\u1ed3i quy c\u1ee7a ch\u00fang t\u00f4i cho th\u1ea5y \u0111\u00e2y l\u00e0 h\u1ec7 s\u1ed1 \u00e2m \u0111\u00e1ng k\u1ec3 nh\u1ea5t (-0.64) \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer. C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 n\u00ean t\u00ednh to\u00e1n t\u1ef7 l\u1ec7 ph\u1ea7n tr\u0103m doanh thu d\u1ec5 b\u1ecb t\u1ed5n th\u01b0\u01a1ng do h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf trong 3-5 n\u0103m t\u1edbi v\u00e0 ti\u1ec1m n\u0103ng thay th\u1ebf t\u1eeb danh m\u1ee5c s\u1ea3n ph\u1ea9m m\u1edbi b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng c\u00e1c m\u00f4 h\u00ecnh NPV \u0111i\u1ec1u ch\u1ec9nh r\u1ee7i ro."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1 nh\u00e2n x\u00e2y d\u1ef1ng m\u00f4 h\u00ecnh x\u00e1c su\u1ea5t c\u1ee7a ri\u00eang h\u1ecd cho c\u1ed5 phi\u1ebfu Pfizer?","answer":"B\u1eaft \u0111\u1ea7u b\u1eb1ng c\u00e1ch thu th\u1eadp \u00edt nh\u1ea5t 5 n\u0103m d\u1eef li\u1ec7u h\u00e0ng qu\u00fd v\u1ec1 t\u0103ng tr\u01b0\u1edfng doanh thu, bi\u00ean l\u1ee3i nhu\u1eadn, chi ti\u00eau R&D v\u00e0 c\u00e1c ph\u00ea duy\u1ec7t c\u1ee7a FDA c\u1ee7a Pfizer. S\u1eed d\u1ee5ng ph\u00e2n t\u00edch h\u1ed3i quy \u0111a bi\u1ebfn \u0111\u1ec3 x\u00e1c \u0111\u1ecbnh nh\u1eefng y\u1ebfu t\u1ed1 n\u00e0o c\u00f3 m\u1ed1i quan h\u1ec7 c\u00f3 \u00fd ngh\u0129a th\u1ed1ng k\u00ea v\u1edbi bi\u1ebfn \u0111\u1ed9ng gi\u00e1 c\u1ed5 phi\u1ebfu (t\u00ecm c\u00e1c gi\u00e1 tr\u1ecb p d\u01b0\u1edbi 0.05). T\u00ednh to\u00e1n h\u1ec7 s\u1ed1 t\u01b0\u01a1ng quan gi\u1eefa c\u00e1c y\u1ebfu t\u1ed1 n\u00e0y v\u00e0 x\u00e2y d\u1ef1ng m\u00f4 h\u00ecnh ch\u1ea5m \u0111i\u1ec3m c\u00f3 tr\u1ecdng s\u1ed1 d\u1ef1a tr\u00ean c\u00e1c h\u1ec7 s\u1ed1 h\u1ed3i quy. Pocket Option cung c\u1ea5p c\u00e1c c\u00f4ng c\u1ee5 c\u00f3 th\u1ec3 gi\u00fap \u0111\u01a1n gi\u1ea3n h\u00f3a qu\u00e1 tr\u00ecnh ph\u00e2n t\u00edch n\u00e0y."},{"question":"Vai tr\u00f2 c\u1ee7a m\u1ea3ng kinh doanh v\u1eafc-xin c\u1ee7a Pfizer trong ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 c\u1ed5 phi\u1ebfu trong t\u01b0\u01a1ng lai l\u00e0 g\u00ec?","answer":"V\u1eafc xin \u0111\u00f3ng g\u00f3p kho\u1ea3ng 21,7% v\u00e0o doanh thu c\u1ee7a Pfizer v\u1edbi CAGR 7,3%. Ph\u00e2n kh\u00fac n\u00e0y c\u00f3 h\u1ec7 s\u1ed1 t\u01b0\u01a1ng quan 0,67 v\u1edbi hi\u1ec7u su\u1ea5t c\u1ed5 phi\u1ebfu t\u1ed5ng th\u1ec3, \u0111\u1eb7t n\u00f3 \u1edf m\u1ee9c \u1ea3nh h\u01b0\u1edfng trung b\u00ecnh. Th\u1eddi gian b\u1ea3o h\u1ed9 b\u1eb1ng s\u00e1ng ch\u1ebf t\u01b0\u01a1ng \u0111\u1ed1i d\u00e0i c\u1ee7a ph\u00e2n kh\u00fac n\u00e0y (trung b\u00ecnh tr\u1ecdng s\u1ed1 6,8 n\u0103m) cung c\u1ea5p s\u1ef1 \u1ed5n \u0111\u1ecbnh doanh thu. Tuy nhi\u00ean, t\u1ed1c \u0111\u1ed9 t\u0103ng tr\u01b0\u1edfng cao h\u01a1n trong c\u00e1c ph\u00e2n kh\u00fac ung th\u01b0 (12,4%) v\u00e0 b\u1ec7nh hi\u1ebfm (15,8%) c\u00f3 th\u1ec3 th\u00fac \u0111\u1ea9y ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 c\u1ed5 phi\u1ebfu l\u1edbn h\u01a1n m\u1eb7c d\u00f9 \u0111\u00f3ng g\u00f3p doanh thu hi\u1ec7n t\u1ea1i c\u1ee7a ch\u00fang nh\u1ecf h\u01a1n."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u1ed5 ch\u1ee9c \u0111\u1ecbnh l\u01b0\u1ee3ng r\u1ee7i ro quy \u0111\u1ecbnh v\u00e0 ch\u00ednh s\u00e1ch khi \u0111\u00e1nh gi\u00e1 Pfizer?","answer":"C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 tinh vi x\u00e2y d\u1ef1ng c\u00e1c m\u00f4 h\u00ecnh d\u1ef1a tr\u00ean k\u1ecbch b\u1ea3n v\u1edbi tr\u1ecdng s\u1ed1 x\u00e1c su\u1ea5t cho c\u00e1c k\u1ebft qu\u1ea3 quy \u0111\u1ecbnh kh\u00e1c nhau. H\u1ecd \u0111\u1ecbnh l\u01b0\u1ee3ng m\u1ee9c \u0111\u1ed9 r\u1ee7i ro ch\u00ednh s\u00e1ch b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng c\u00e1c ch\u1ec9 s\u1ed1 nh\u01b0 Doanh thu c\u00f3 R\u1ee7i ro t\u1eeb Ki\u1ec3m so\u00e1t Gi\u00e1, Ch\u1ec9 s\u1ed1 \u0110a d\u1ea1ng h\u00f3a Doanh thu \u0110\u1ecba l\u00fd v\u00e0 H\u1ec7 s\u1ed1 Nh\u1ea1y c\u1ea3m Ch\u00ednh s\u00e1ch (\u0111o l\u01b0\u1eddng ph\u1ea3n \u1ee9ng gi\u00e1 c\u1ed5 phi\u1ebfu l\u1ecbch s\u1eed \u0111\u1ed1i v\u1edbi c\u00e1c th\u00f4ng b\u00e1o ch\u00ednh s\u00e1ch quan tr\u1ecdng). C\u00e1c m\u00f4 ph\u1ecfng Monte Carlo k\u1ebft h\u1ee3p c\u00e1c bi\u1ebfn s\u1ed1 n\u00e0y v\u1edbi c\u00e1c ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t ph\u00f9 h\u1ee3p \u0111\u1ec3 m\u00f4 h\u00ecnh h\u00f3a c\u00e1c k\u1ebft qu\u1ea3 ph\u1ea1m vi d\u01b0\u1edbi c\u00e1c k\u1ecbch b\u1ea3n quy \u0111\u1ecbnh kh\u00e1c nhau."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"C\u00e1c ch\u1ec9 s\u1ed1 t\u00e0i ch\u00ednh quan tr\u1ecdng nh\u1ea5t c\u1ea7n theo d\u00f5i khi ph\u00e2n t\u00edch li\u1ec7u c\u1ed5 phi\u1ebfu Pfizer c\u00f3 t\u0103ng hay kh\u00f4ng l\u00e0 g\u00ec?","answer":"C\u00e1c ch\u1ec9 s\u1ed1 quan tr\u1ecdng bao g\u1ed3m T\u1ef7 su\u1ea5t D\u00f2ng ti\u1ec1n T\u1ef1 do, T\u1ef7 l\u1ec7 N\u0103ng su\u1ea5t R&D (\u0111o l\u01b0\u1eddng doanh thu t\u1ea1o ra tr\u00ean m\u1ed7i \u0111\u00f4 la chi ti\u00eau cho R&D), T\u1ef7 l\u1ec7 P\/E \u0111i\u1ec1u ch\u1ec9nh b\u1eb1ng B\u1eb1ng s\u00e1ng ch\u1ebf, EBITDA\/Gi\u00e1 tr\u1ecb Doanh nghi\u1ec7p, v\u00e0 T\u1ef7 su\u1ea5t L\u1ee3i nhu\u1eadn Ti\u1ec1n m\u1eb7t tr\u00ean V\u1ed1n \u0110\u1ea7u t\u01b0. Nh\u1eefng ch\u1ec9 s\u1ed1 n\u00e0y cung c\u1ea5p c\u00e1i nh\u00ecn s\u00e2u s\u1eafc h\u01a1n so v\u1edbi ch\u1ec9 s\u1ed1 P\/E truy\u1ec1n th\u1ed1ng. X\u00e1c su\u1ea5t chuy\u1ec3n \u0111\u1ed5i danh m\u1ee5c v\u00e0 c\u00e1c ch\u1ec9 s\u1ed1 \u0111a d\u1ea1ng h\u00f3a doanh thu c\u0169ng quan tr\u1ecdng kh\u00f4ng k\u00e9m \u0111\u1ed1i v\u1edbi c\u00e1c c\u1ed5 phi\u1ebfu d\u01b0\u1ee3c ph\u1ea9m nh\u01b0 Pfizer."},{"question":"S\u1ef1 h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf \u1ea3nh h\u01b0\u1edfng nh\u01b0 th\u1ebf n\u00e0o \u0111\u1ebfn \u0111\u1ecbnh gi\u00e1 c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer?","answer":"C\u00e1c b\u1eb1ng s\u00e1ng ch\u1ebf h\u1ebft h\u1ea1n t\u1ea1o ra nh\u1eefng g\u00ec m\u00e0 c\u00e1c nh\u00e0 ph\u00e2n t\u00edch g\u1ecdi l\u00e0 \"v\u00e1ch \u0111\u00e1 b\u1eb1ng s\u00e1ng ch\u1ebf\" - nh\u1eefng giai \u0111o\u1ea1n khi doanh thu t\u1eeb c\u00e1c lo\u1ea1i thu\u1ed1c h\u00e0ng \u0111\u1ea7u ph\u1ea3i \u0111\u1ed1i m\u1eb7t v\u1edbi s\u1ef1 c\u1ea1nh tranh t\u1eeb thu\u1ed1c generic. Ph\u00e2n t\u00edch h\u1ed3i quy c\u1ee7a ch\u00fang t\u00f4i cho th\u1ea5y \u0111\u00e2y l\u00e0 h\u1ec7 s\u1ed1 \u00e2m \u0111\u00e1ng k\u1ec3 nh\u1ea5t (-0.64) \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn c\u1ed5 phi\u1ebfu c\u1ee7a Pfizer. C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 n\u00ean t\u00ednh to\u00e1n t\u1ef7 l\u1ec7 ph\u1ea7n tr\u0103m doanh thu d\u1ec5 b\u1ecb t\u1ed5n th\u01b0\u01a1ng do h\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf trong 3-5 n\u0103m t\u1edbi v\u00e0 ti\u1ec1m n\u0103ng thay th\u1ebf t\u1eeb danh m\u1ee5c s\u1ea3n ph\u1ea9m m\u1edbi b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng c\u00e1c m\u00f4 h\u00ecnh NPV \u0111i\u1ec1u ch\u1ec9nh r\u1ee7i ro."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 c\u00e1 nh\u00e2n x\u00e2y d\u1ef1ng m\u00f4 h\u00ecnh x\u00e1c su\u1ea5t c\u1ee7a ri\u00eang h\u1ecd cho c\u1ed5 phi\u1ebfu Pfizer?","answer":"B\u1eaft \u0111\u1ea7u b\u1eb1ng c\u00e1ch thu th\u1eadp \u00edt nh\u1ea5t 5 n\u0103m d\u1eef li\u1ec7u h\u00e0ng qu\u00fd v\u1ec1 t\u0103ng tr\u01b0\u1edfng doanh thu, bi\u00ean l\u1ee3i nhu\u1eadn, chi ti\u00eau R&D v\u00e0 c\u00e1c ph\u00ea duy\u1ec7t c\u1ee7a FDA c\u1ee7a Pfizer. S\u1eed d\u1ee5ng ph\u00e2n t\u00edch h\u1ed3i quy \u0111a bi\u1ebfn \u0111\u1ec3 x\u00e1c \u0111\u1ecbnh nh\u1eefng y\u1ebfu t\u1ed1 n\u00e0o c\u00f3 m\u1ed1i quan h\u1ec7 c\u00f3 \u00fd ngh\u0129a th\u1ed1ng k\u00ea v\u1edbi bi\u1ebfn \u0111\u1ed9ng gi\u00e1 c\u1ed5 phi\u1ebfu (t\u00ecm c\u00e1c gi\u00e1 tr\u1ecb p d\u01b0\u1edbi 0.05). T\u00ednh to\u00e1n h\u1ec7 s\u1ed1 t\u01b0\u01a1ng quan gi\u1eefa c\u00e1c y\u1ebfu t\u1ed1 n\u00e0y v\u00e0 x\u00e2y d\u1ef1ng m\u00f4 h\u00ecnh ch\u1ea5m \u0111i\u1ec3m c\u00f3 tr\u1ecdng s\u1ed1 d\u1ef1a tr\u00ean c\u00e1c h\u1ec7 s\u1ed1 h\u1ed3i quy. Pocket Option cung c\u1ea5p c\u00e1c c\u00f4ng c\u1ee5 c\u00f3 th\u1ec3 gi\u00fap \u0111\u01a1n gi\u1ea3n h\u00f3a qu\u00e1 tr\u00ecnh ph\u00e2n t\u00edch n\u00e0y."},{"question":"Vai tr\u00f2 c\u1ee7a m\u1ea3ng kinh doanh v\u1eafc-xin c\u1ee7a Pfizer trong ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 c\u1ed5 phi\u1ebfu trong t\u01b0\u01a1ng lai l\u00e0 g\u00ec?","answer":"V\u1eafc xin \u0111\u00f3ng g\u00f3p kho\u1ea3ng 21,7% v\u00e0o doanh thu c\u1ee7a Pfizer v\u1edbi CAGR 7,3%. Ph\u00e2n kh\u00fac n\u00e0y c\u00f3 h\u1ec7 s\u1ed1 t\u01b0\u01a1ng quan 0,67 v\u1edbi hi\u1ec7u su\u1ea5t c\u1ed5 phi\u1ebfu t\u1ed5ng th\u1ec3, \u0111\u1eb7t n\u00f3 \u1edf m\u1ee9c \u1ea3nh h\u01b0\u1edfng trung b\u00ecnh. Th\u1eddi gian b\u1ea3o h\u1ed9 b\u1eb1ng s\u00e1ng ch\u1ebf t\u01b0\u01a1ng \u0111\u1ed1i d\u00e0i c\u1ee7a ph\u00e2n kh\u00fac n\u00e0y (trung b\u00ecnh tr\u1ecdng s\u1ed1 6,8 n\u0103m) cung c\u1ea5p s\u1ef1 \u1ed5n \u0111\u1ecbnh doanh thu. Tuy nhi\u00ean, t\u1ed1c \u0111\u1ed9 t\u0103ng tr\u01b0\u1edfng cao h\u01a1n trong c\u00e1c ph\u00e2n kh\u00fac ung th\u01b0 (12,4%) v\u00e0 b\u1ec7nh hi\u1ebfm (15,8%) c\u00f3 th\u1ec3 th\u00fac \u0111\u1ea9y ti\u1ec1m n\u0103ng t\u0103ng gi\u00e1 c\u1ed5 phi\u1ebfu l\u1edbn h\u01a1n m\u1eb7c d\u00f9 \u0111\u00f3ng g\u00f3p doanh thu hi\u1ec7n t\u1ea1i c\u1ee7a ch\u00fang nh\u1ecf h\u01a1n."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u1ed5 ch\u1ee9c \u0111\u1ecbnh l\u01b0\u1ee3ng r\u1ee7i ro quy \u0111\u1ecbnh v\u00e0 ch\u00ednh s\u00e1ch khi \u0111\u00e1nh gi\u00e1 Pfizer?","answer":"C\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 tinh vi x\u00e2y d\u1ef1ng c\u00e1c m\u00f4 h\u00ecnh d\u1ef1a tr\u00ean k\u1ecbch b\u1ea3n v\u1edbi tr\u1ecdng s\u1ed1 x\u00e1c su\u1ea5t cho c\u00e1c k\u1ebft qu\u1ea3 quy \u0111\u1ecbnh kh\u00e1c nhau. H\u1ecd \u0111\u1ecbnh l\u01b0\u1ee3ng m\u1ee9c \u0111\u1ed9 r\u1ee7i ro ch\u00ednh s\u00e1ch b\u1eb1ng c\u00e1ch s\u1eed d\u1ee5ng c\u00e1c ch\u1ec9 s\u1ed1 nh\u01b0 Doanh thu c\u00f3 R\u1ee7i ro t\u1eeb Ki\u1ec3m so\u00e1t Gi\u00e1, Ch\u1ec9 s\u1ed1 \u0110a d\u1ea1ng h\u00f3a Doanh thu \u0110\u1ecba l\u00fd v\u00e0 H\u1ec7 s\u1ed1 Nh\u1ea1y c\u1ea3m Ch\u00ednh s\u00e1ch (\u0111o l\u01b0\u1eddng ph\u1ea3n \u1ee9ng gi\u00e1 c\u1ed5 phi\u1ebfu l\u1ecbch s\u1eed \u0111\u1ed1i v\u1edbi c\u00e1c th\u00f4ng b\u00e1o ch\u00ednh s\u00e1ch quan tr\u1ecdng). C\u00e1c m\u00f4 ph\u1ecfng Monte Carlo k\u1ebft h\u1ee3p c\u00e1c bi\u1ebfn s\u1ed1 n\u00e0y v\u1edbi c\u00e1c ph\u00e2n ph\u1ed1i x\u00e1c su\u1ea5t ph\u00f9 h\u1ee3p \u0111\u1ec3 m\u00f4 h\u00ecnh h\u00f3a c\u00e1c k\u1ebft qu\u1ea3 ph\u1ea1m vi d\u01b0\u1edbi c\u00e1c k\u1ecbch b\u1ea3n quy \u0111\u1ecbnh kh\u00e1c nhau."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc &amp; Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc &amp; Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-01T06:05:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tatiana OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatiana OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\"},\"author\":{\"name\":\"Tatiana OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"headline\":\"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc &#038; Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n\",\"datePublished\":\"2025-08-01T06:05:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp\",\"keywords\":[\"investment\",\"stock\",\"strategy\"],\"articleSection\":[\"Trading\"],\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\",\"name\":\"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc & Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp\",\"datePublished\":\"2025-08-01T06:05:01+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#breadcrumb\"},\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/vt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc &#038; Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vt-VT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\",\"name\":\"Tatiana OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"caption\":\"Tatiana OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/author\/tatiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc & Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/","og_locale":"en_US","og_type":"article","og_title":"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc & Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n","og_url":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-01T06:05:01+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp","type":"image\/webp"}],"author":"Tatiana OK","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatiana OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/"},"author":{"name":"Tatiana OK","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"headline":"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc &#038; Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n","datePublished":"2025-08-01T06:05:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp","keywords":["investment","stock","strategy"],"articleSection":["Trading"],"inLanguage":"vt-VT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/","url":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/","name":"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc & Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp","datePublished":"2025-08-01T06:05:01+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#breadcrumb"},"inLanguage":"vt-VT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/"]}]},{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/04\/1740502088543-611516886-17.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/vt\/"},{"@type":"ListItem","position":2,"name":"C\u1ed5 phi\u1ebfu Pfizer s\u1ebd t\u0103ng: Ph\u00e2n t\u00edch khoa h\u1ecdc &#038; Ch\u1ec9 s\u1ed1 d\u1ef1 \u0111o\u00e1n"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/vt\/#website","url":"https:\/\/pocketoption.com\/blog\/vt\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vt-VT"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d","name":"Tatiana OK","image":{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","caption":"Tatiana OK"},"url":"https:\/\/pocketoption.com\/blog\/vt\/author\/tatiana\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"vt_VT","wpml_translations":{"pt_AA":{"locale":"pt_AA","id":327923,"slug":"will-pfizer-stock-go-up","post_title":"O estoque da Pfizer vai subir: An\u00e1lise cient\u00edfica e m\u00e9tricas preditivas","href":"https:\/\/pocketoption.com\/blog\/pt\/knowledge-base\/trading\/will-pfizer-stock-go-up\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/327928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/comments?post=327928"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/327928\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media\/251337"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media?parent=327928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/categories?post=327928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/tags?post=327928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}